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Abstract
Duchenne Muscular Dystrophy (DMD) is a genetic disorder which is caused by mutations
in the dystrophin gene. One of the functions of this protein is to anchor the cell membrane
to the sacrolemma. In DMD, the absence of this protein leads to muscle damage during
contractions, resulting in continuous regeneration and repair of the muscle until the
replicative ability of the muscle is exhausted. The consequence of this loss is loss of
muscle mass and death of the patients in the third decade of life due to respiratory failure.
There have been many attempts to cure this disorder including the strategy of gene and cell
therapy. Although these approaches have had some success in animal models there has
been no improvement in human trials. At present the treatment of DMD consists of steroid
therapy and supportive treatment.
The aim of my work was to test the hypothesis that the transduction of telomerase in to
muscle cells could produce a non transformed muscle cells with unlimited growth potential
that could in principal, could serve as a target cell population for human dystrophin gene
therapy.
The expression of the catalytic subunit of telomerase (hTERT) has been successfully used
to extend the lifespan of a number of different cell types without malignant transformation.
However previous attempts to immortalise muscle cells in this manner had failed. Here I
report the successful immortalisation of normal human skeletal muscle cells by retroviral
infection of hTERT. The telomerase positive cells display an extended lifespan, with 4/5
clones exceeding 120 MPD. The clones show no feature of transformation in vitro, retain a
stable diploid karyotype, have wild type unmethylated CDKN2A genes and do not express
muscle specific markers desmin and spectrin. In vivo, they can repair and reconstitute
muscle in immunosuppressed RAG-1 mice. These results suggest that telomerase
expression can extend lifespan of human muscle cells and could aid attempts at gene
therapy for muscle diseases.
Introduction
A major advance in medical research has been the ability to remove cells from human and
animal tissues and grow them in an artificial environment. The development of various
media and the use of specialized incubators have allowed cell types to be examined in
terms of their DNA, their growth properties and the changes which occur in them in
diseased states. It was thought that under optimal growth conditions all cells had an
unlimited ability to replicate until the work of Hayflick and Moorhead (1, 2) showed that
this was not so: on the contrary, with certain exceptions cells have a strictly limited growth
potential. The exceptions are germline cells, immortalized tissue culture cell lines and
cancer cells which will indeed proliferate continuously. In vitro, normal somatic cells
eventually age and stop proliferating, i.e. become senescent.
The replicative capacity of cells limits the lifespan of key systems in the body and the
genetic programme that directs this process was elucidated by the work of Hayflick and
others (1, 2). They were the first to show that, as predicted by the German biologist August
Weismann (3), somatic cells of higher animals have a limited doubling potential (as cited
in (4». Weismann had no experimental evidence for his hypothesis but he stated that
"death takes place because a worn-out tissue cannot forever renew itself and because a
capacity for increase by means of cell division is not everlasting but finite"
This important experimental work of Hayflick et al confirmed that cells in culture replicate
only for a finite number of divisions. In their seminal studies they took fibroblasts in
culture and divided them into two parts, in one continual growth was allowed, until it
ceased. The other sample was preserved cryogenically. When the latter cells were brought
back to culture conditions and grown, they underwent the same number of daub lings as the
other set and then stopped growing. It thus appeared that the cells had been programmed
to grow for a set number of divisions and then stop (1).
These workers suggested that their findings represented aging at the cellular level. Their
aim was to identify the putative cell division counting mechanism which they postulated
must exist (5) but it is only in the last few years that this has been achieved. It has now
been confirmed that the shortening of telomeres at each round of DNA replication that
occurs in normal cells in vivo and in vitro represents the functioning "mitotic clock".
Rounds of DNA replication are measured until a limit is reached: "the Hayflick limit"(2).
2The arrest of cell division which eventually occurs represents the finite replicative lifespan
of the cell and leads to the process called replicative or cell senescence.
Hayflick deduced several important points from his work: first, that there is an inverse
relationship between donor age and population daub lings (of great importance in
considering cell transfer therapy, as will be discussed later). Secondly, the same changes in
biological activity which are seen in vitro can be recognised as characteristic of aging in
the human. Thirdly, there is a direct relationship between species lifespan and the
population doublings of their cultured normal cells, suggesting that aging does not only
represent terminal differentiation but is related to other events occurring in these cells
which may limit their usual abilities (2).
It has become apparent that although the fields of aging and cancer research differ greatly
they are linked by studies into cellular aging, proliferative capacity and the development of
malignancy (6). A common hypothesis has been suggested based on the view that telomere
shortening is the molecular measure (mitotic clock) of the proliferative capacity remaining
in cells (6). Telomeres can be maintained without any shortening by the enzyme
telomerase. This enzyme is not expressed in the majority of normal human somatic cells
but it is found in germ line cells, immortal cells in culture and malignant cells. Most
malignant tumours acquire immortality and then proliferate continuously and this ability
depends on allowing the re-expression of telomerase. Without this, telomeric DNA is lost
from the ends of chromosomes every time cells divide due to the end replication problem.
The cells become senescent in this state, they may still remain metabolically active and
resist apoptotic death for long periods (7). Research into the mechanism and regulation of
telomerase has been extensive, in the hope that it will provide an insight into the processes
of aging, immortalisation and cancer (6).
1. 1. Mitotic clock
Hayflick's concept of the mitotic clock (1, 2, 5), was seminal in the study of cell
replication: much experimental work now supports his view that cellular aging is
dependent on the number of cell divisions while total cellular life span is measured by the
number of population doublings or cell generations, not by chronological time. The mitotic
clock functions by counting the number of such cell divisions. In eukaryotic cells, the
process involves evaluating the progressive loss of telomeric repeats at the ends of the
chromosomes (see figure 1.1), which occurs during the aging process in vitro and in vivo.
3Evidence indicates that this loss eventually induces antiproliferative signals, resulting in
cellular senescence (6).
The mitotic clock is therefore a timing mechanism. It regulates cellular senescence based
on the normal, progressive loss of telomeres. In support of this hypothesis, the growth of
most continuously replicating cells depends on activation of telomerase, a
ribonucleoprotein enzyme which maintains telomere length and stability.
Figure 1.1 Schematic representation of the telomere structure
Demonstrates the position of the telomere, the subtelomeric region, the coding DNA and
the centromere.
Adapted from Checkpoint Controls and Cancer, Volume 2, Activation and regulation
protocols, Edited by Axel H. Schonthal, Page 340
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Figure 1.1 Schematic representation of the telomere structure
61.2 Cellular lifespan and senescence
Replicative or cellular senescence is the irreversible growth arrest which occurs when
human diploid cells reach the end of their proliferative potential when serially cultured (5).
It is thought that this mechanism has evolved to protect the cell against tumorogenesis (8).
A senescent cell not only stops replicating but displays a different phenotype (9). The cells
become enlarged, multi-nucleated and flat and they also show increased staining for ~-
galactosidase at pH 6 (7). As the cell approaches senescence, there is also an increase in
the cyelin-dependent kinase inhibitors pI6INK4a and p2I Cipl which leads to cell cycle arrest
(see below) (10).
1.2. 1 Cell cycle arrest
The cell cycle is a highly ordered and structured process. DNA must be accurately
replicated and identical chromosomes distributed into two daughter cells. The cycle is
divided into four distinct phases Le. GO, GI, Mitosis and S phase (DNA synthesis). GI is
the gap where the cell can exit the cyele and stay quiescent (GO) (see figure 1.2). During
GI there is a restriction point where gene transcription is tightly regulated (see figure 1.3)
(11-13). INK4a/ARF encodes two distinct proteins, pI6INK4a and plgARF (mouse) or pI4ARF
(human), which when expressed result in cell cyele arrest (figure 1.3 and 1.4). pI6 binds
directly to the cyclin dependent kinases (Cdks) 4 and 6 and blocks the phosphorylation of
the retinoblastoma gene product (PRB) and the release of the transcription factor E2F. This
results in the cells arresting in the Gl phase of the cell cycle. p14ARF / plgARF interact
directly with MDM2 and lead to the stabilisation of p53 and cause the cell to arrest in GI
or G2. The accumulation of p53 also leads to the increased expression of the p53-regulated
gene p21Cipl.
Figure 1.2 The cell cycle
Schematic diagram of the cell cycle, showing the position of the G1 restriction point in
relation to the other phases.
Adapted from Stem Cells 2001;19: 1, Pages 88 -91, E.D. Israels & L.G. Israels, The Cell
Cycle
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Figure 1.2 The cell cycle
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Figure 1.3 The G1 restriction checkpoint
Schematic diagram showing the relationship between the cell cycle regulators and the
phosphoyrlation of RB. The yellow arrow indicates a positive response on the following
activator, while the pink arrow represents an inhibitory response.
Adapted from Stem Cells 2001;19: 1, Pages 88 -91, E.D. Israels & L.G. Israels, The Cell
Cycle
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Figure 1.3 The G1 restriction checkpoint
Figure 1.4 The structure of the INK4a locus
The splicing pattern to generate the 2 proteins is shown below the schematic. Note that
p14ARF and pl6INK4aare translated from exon 2 in different reading frames and terminate in
different exons. p14ARF is terminated in exon 2 while p16 stops in exon 3.
Adapted from Voorhoeve, P. M (2003) The tumour-suppressor functions of the human
INK4A locus, Cancer Cell, 4; 4: 311 - 319
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Figure 1.7 The structure INK4a locus
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1.2.2 Mortality checkpoints
Cellular senescence can be divided into 3 components: mortality stage 0 (MO), mortality
stage 1 (M1) and mortality stage 2 (M2) (see figure 1.5) (10). In culture normal diploid
cells will undergo a number of population doublings before they arrive at a barrier to
proliferation. As a cultured epithelial cell approaches senescence it accumulates p16 and
reaches MO. This checkpoint is dependent on p16. If a cell has dysfunctional p16 it can
bypass this barrier and continue growing until it reaches M1 or senescence (14). At this
stage the checkpoint is dependent on pS3 and pRB. Disruption of these proteins allows the
cell to proliferate until M2 or crisis (13). Unlike senescence, there is cellular proliferation
during crisis (15), however, there is also a high rate of cell death resulting in no net growth
in the cultures. M2 can be overcome if telorne rase is reactivated or if the telomeres are
extended due to ALT (Alternative Lengthening of Telomerase) (16). If a cell can reach
this point, it is immortalised. It has been noted that the effects of the cell cycle regulators
involved in the senescence checkpoint can be overcome by the effect of oncogenic agents,
such as SV40 T antigen, or papilloma virus E6 and E7 proteins. In addition, mutations in
the key regulators of the checkpoint, pS3, pRB and p16 are common in many different
tumour cell types.
Figure 1.5 Models of senescence and immortalisation.
Graph showing the growth arrest checkpoints MO, Ml and Jv12 in relation to MPD, the
alterations that must take place for the cells to escape from these checkpoints and the
outcome for those cells which do escape.
Adapted from European Journal of Cancer, 1997, 33; 5: pages 703 - 709, The Biology of
Replicative Senescence.
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Figure 1.5 Models of senescence and immortalisation
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1.2.2.1 MOcheckpoint and p16/p19ARF regulation
As indicated above, p16 is coded on the INK4A locus along with p19ARF (12). These are a
family of CDK inhibitors with p16 inhibiting CDK4/6 and p19ARF by binding to MDM2
preventing the destruction of p53. This results in an increase in p53 which then leads to an
increase in p21 due to the inhibition of CDK6 and CDK4. The inhibition of CDK4/6 by
p16 prevents phosphorylation of RB and the cell remains in G1 and cannot replicate (17).
If p16 is inactivated by methylation or is mutated (18, 19) the cells will continue
proliferating and bypass MO to go on to MI.
1.2.2.2 M1 and p53/RB regulation
RB is known as the "gatekeeper" protein in cell cycle regulation (12, 17). RB is a pocket
protein which when unphosphorylated binds to E2F. While E2F is bound to RB it cannot
bind to DNA and activate E2F responsive genes. RB can be phosphorylated by CDK4/6
and the cyclin D complex. This results in the release of E2F and the cell can continue
through the cell cycle. Transcription factor p53 is another important regulator and is known
as "guardian of the genome" (13). In the presence of DNA damage, p53 interrupts the
cycle and allows time for the DNA repair mechanisms. This is achieved by p53 inhibiting
RB phosphorylation and preventing transcription. In M1, if RB and p53 normal function is
blocked, for example by introducing SV40 T-antigen into the cells, then the cells will
continue to proliferate.
1.2.2.3 M2 and telomerase
By the time a cell has gone through MO and M1 there has been a great amount of genetic
alterations and many cell cycle regulators are lost (12). Throughout this proliferative
period the telomeric repeats at the ends of the chromosomes will become increasingly
shorter (discussed in detail later). At M2 the telomeres reach a critically short length and
the majority of cells have entered crisis. Crisis is different from senescence as there is
continued growth (15). However, this is accompanied by apoptosis so that there is no net
increase in cell number. Most cells will stay in a state of crisis but a rare cell may bypass
this by reactivating telomerase and increasing the length of its telomeres. These cells will
now become immortal.
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1.3 Te/omeres
1.3. 1 Telomeric DNA and replication
Telomeres are structures at the ends of eukaryotic linear chromosomes (see figure 1.1).
They derive their name from the Greek word le/os meaning end and meres, a component.
They consist of the simple, repetitive sequence of TTAGGG (20), varying in size from 6-
26 kilobase pairs in humans and other vertebrates, together with specialised proteins, and
are highly conserved throughout evolution (21). The presence of such structures was
predicted before they were identified by Olovnikov (22) and Watson (23) since it had been
already shown that, before a cell divides, it must replicate its DNA. However the telomeres
at the ends of the chromosomes are not completely replicated due to the 'end replication
problem' (see figure 1.6). DNA polymerases replicate DNA in a 5' to 3' direction only and
require an 8-12 base pair RNA primer to initiate DNA synthesis. The replication of the
leading strand is continuous but the lagging strand is synthesized by the ligation of short
DNA fragments (Okazaki fragments). The removal of the RNA primers at the 5' ends of
the newly synthesized strand results in a short single stranded 3' overhang in the other
strand. The progressive loss of telomeric sequences continues each time a normal somatic
cell divides until a critical length is reached and the cell will no longer divide i.e. has
reached senescence (24-26). In addition, telomeric sequences may also be lost by
exonuclease digestion (27) and oxidative damage (28). The constant shortening of the
telomere results in the telomere t-loop being unable to form. The telomere can no longer
protect the ends of the chromosomes and these results in chromosomes fusing and
degrading. The result of this is that the cells enter growth arrest (29).
The end replication problem is overcome by germ cells and the majority of cancer cells by
the activation of the enzyme complex telomerase, which maintains telomere lengths above
a threshold and allows the cells to proliferate indefinitely.
Figure 1.6 The end replication problem
A. DNA polymerase replicates DNA in a 5' to 3' direction utilising an RNA primer. The
leading strand is replicated continuously whereas the lagging strand is synthesised from
short DNA fragments (Okazaki fragments) which are subsequently joined together by
DNA ligase.
B-C. Removal of the RNA primer at the 5' end of the newly synthesised strand results in a
'gap' creating a 3' overhang in the complimentary strand.
D. During each cycle of DNA replication there is progressive shortening of the 5' ends (red
and green) which contributes to the shortening of telomeric sequences in the absence of
telomerase.
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1.3.2 Telomere function
Telomeres are capping structures which protect the ends of the chromosome against
degradation and prevent them from being recognised as double strand breaks (DSB) by the
DNA repair machinery (21, 30). Their other functions are in preventing the loss of
heterozygosity (31), chromosomal translocations (32), deletions and loss of information,
all of which could lead to cell death (33). Without telomeres, the ends of chromosomes are
subject to the same degradation or random fusion which leads to activation of the DNA
repair system and disruption of cell cycle checkpoints. Short dysfunctional telomeres are
interpreted by the cell as a DSB and fuse resulting in dicentric chromosomes. The dicentric
chromosomes are replicated during S-phase and result in anaphase bridging during mitosis.
The dicentric chromosome then breaks during telophase and can enter into a breakage
fusion breakage (BFB) cycle in further rounds of replication (see figure 1.7). In normal
somatic cells these DSBs would be recognised by the DNA repair machinery and repaired
or the cell would undergo apoptosis. However in cancer cells which may have lost cell
cycle checkpoints (e.g. pS3 and pRB) the increase in DSB and BFB cycle contributes to
genomic instability and the gains and losses associated with cancer. It can be seen that
telomeres provide the major role in protecting the coding DNA in chromosomes.
Figure 1.7 Telomeric erosion and the generation of dicentric chromosomes
and anaphase bridges
As cells divide in the absence of telomerase, the telomere shortens as depicted in red (A).
This exposes the ends of the chromosomes and these are seen as double strand breaks
(DSB) by the DNA repair machinery. They fuse to form a dicentric chromosome e.g.
fusion of two sister chromatids (green and purple) (B). The dicentric chromosome is
replicated during S-phase (C) and these results in anaphase bridging during segregation in
mitosis (D and E). The dicentric chromosome breaks when pulled to opposite spindle poles
resulting in a double strand break [DSB (F)] it causes in changes in gene dosage
[amplifications -amps and deletions -del (G)]. The broken chromosome must be repaired
again and can enter a breakage fusion breakage (BRB) cycle and facilitate the genomic
instability associated with cancer.
Taken from Checkpoint Controls in Cancer 2004 p344
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1.3.3 Telomeric structure
It can be seen from the above that the structure of telomeres is very important in
maintaining genomic stability. Their ends are arranged in a large loop called the telomeric t
loop (see figure 1.8). Electron microscopy has shown that the loop can be several kb large
while indirect evidence has suggested that the 3' overhang is buried deep within the
junction between the t loop and the tail (34). It is thought that this structure prevents the 3'
overhang from being seen as a DNA break and therefore degraded. The single stranded 3'
overhang invades and hybridises with a region of double strand telomeric DNA which
displaces genomic DNA to form a structure called a D-Ioop. The formation of t loops
depends critically on TRF2 and disruption of its function can cause tumour cells to die.
The disruption of the t loop structure results in critically short telomeres, leading to cell
death (35) or senescence (36).
1.3.4. Telomere-associated proteins
Many proteins associate with telomeres to differing degrees. The two proteins which are
involved exclusively in mammals are TRF1 and TRF2 (37, 38). These bind the double
stranded telomeric DNA. TIN2 and hRAP1 localise to telomeres but this is through
binding to TRF1 or TRF2 (39, 40). It is thought that these four proteins have a role in
maintaining in regulating the length and structure of the telomere. Some proteins which are
associated with telomeres also localize to other sites. An example is TANK1 (also known
as tankyrase). This is a poly-ADP ribosylase which is associated with DNA repair.
Recently it has been discovered that this also interacts with TRF1 under certain
circumstances (41). Other proteins which are involved with double strand breaks have
also been localised to TRF1 including Ku (42). Ku is essential for repair of double strand
breaks by non-homologous end binding. It is thought that this protects the terminal
telomeric structure. As yet only a few mammalian telomeric-associated proteins have been
identified, however, the extensive list of yeast telomere-associated proteins suggests that
this list is still to be expanded (43).
Figure 1.8 Telomeric t-Ioop and associated binding proteins
Schematic diagram of the telomere structure and associated proteins. Most of the telomeric
DNA is packed into nucleosomes, however the end is attached to associated proteins. The
basic t-loop and d-loop structure is seen in A and the placement of associated proteins in B.
Adapted from EMBO Reports, 2002, 3:12; pages 1139-1145, Rhodes et al, Telomere
architecture
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1.3.5 Telomere length and cellular lifespan
There are hundreds of thousands of telomeric repeats in mammalian cells and these
correlate with the life span of the cell (30, 44, 45) . Cells with longer telomeres undergo
more divisions than those with shorter telomeres. Telomere shortening is also seen in vivo
- in a variety of tissues, telomeres are shorter in older individuals than in younger ones (46-
48).
Regulation of telomere length in mammalian cells is complex. Human sperm telomeres
are longer than those in somatic cells. Length also differs between normal somatic and
malignant cells. The average telomere length in colorectal carcinoma and ovarian
carcinoma is shorter than that in the corresponding normal tissue from the same individual
(6).
There is also variation between species: In mice telomere restriction fragment lengths up to
several hundred kilo base pairs are found (45, 49). The length is similar in different tissues
in the newborn mouse, but differs in the tissues of the adult. It is interesting that
immortalisation of primary mouse cells in culture appears to be relatively easy compared
to its achievement in human cells and this may reflect the presence of telornerase in the
tissues (see later).
Regulation of proliferation is thought to playa role in protection against carcinogenesis:
Cancer incidence increases with age in keeping with a requirement for "multiple hits" in its
development. Long-lived species may have more complex control mechanisms to limit
cellular proliferation than short-lived ones (50, 51). Inhibition of telomerase activity may
be one mechanism which exists in humans, to limit replicative potential (52).
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1.3.6 Telomere attrition
There are thousands of the repeats of the sequence TTAGGG in human cells but the mean
telomere length decreases by 50 - 150 base pairs at each division (attrition). As previously
described, a cell will replicate until the telorneres reach a critical short length when a
damage signal is triggered which will induce senescence. Not all telomeres in the cell will
be shortened to the same length but it is the shortest telomere, rather than the average
telomere length, which determines whether the cell continues replication or enters
senescence (45, 53, 54). The mechanism for this is not completely understood but it is
thought to involve the uncapping of the telomere since an uncapped telomere can trigger
cell cycle arrest or apoptosis. Short telomeres are seen as uncapped. Uncapping of
telomeres can be induced by disruption of the telomere structure and this can be achieved
by expression of a dominant negative form of TRF2 REF. In contrast, synthesis and
capping of the telomeres can be induced by telomerase expression and the dynamic state of
telomeres can then be maintained.
Another proposed mechanism by which shortening of the telomere may signal growth
arrest, is that the short telomere is recognised as a DSB and this induces a p53 dependent
growth arrest (24, 55, 56)
1.3.7 Telomere hypothesis
There has been great interest in the telomere hypothesis of cellular aging. This hypothesis
assumes that telomerase, the enzyme responsible for maintaining telomere length, is active
during gametogenesis (allowing for long-term viability of the germ cell life) but is
repressed during somatic cell differentiation, accounting for the loss of telomeric DNA
associated with the finite replicative capacity of these cells (25, 57). Thus telomere length
and telomerase activity provide valuable biomarkers of the replicative capacity of cells and
may be causally involved in cellular aging, immortalisation and neoplasia (58).
Two key assumptions underlie the hypothesis:- (1) a small amount of DNA from
telomeres is lost with each round of DNA replication and (2) deletions accumulate,
eventually leading to cellular senescence. With regard to germ line and tumour cells,
which are immortal, the hypothesis proposes that special mechanisms exist in them to
prevent deletions and senescence (10).
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1.4 Te/omerase
1.4. 1 Definition
Telomerase is a reverse transcriptase ribonucleoprotein which synthesises telomeric DNA
onto the ends of chromosomes. It copies an RNA template into DNA but is unusual in that
it contains its own RNA template as an integral part of the enzyme. The enzyme was first
discovered in Tetrahymena (59) but was later found to be present in all eukaryotes, and
although varying between species, it showed conservation of structure and function (60).
Telomerase is comprised of 2 subunits: hTER which is the RNA component acting as a
template for the polymerase activity of the enzyme, and hTERT which is the catalytic
component with reverse transcriptase activity (61). Both components are required in vitro
to reconstitute telomerase activity. However it is thought that hTERT is the rate-limiting
step in telomerase activity and for this reason hTERT gene expression and regulation is
now at the forefront of telomerase research. Telomerase is expressed in germline cells and
in developing tissue: During some point in development, thought to be at differentiation,
the cell will switch off the expression of telomerase (62).
1.4.2 Isolation, identification and measurement of telomerase
Activity
Telomerase was first identified by Greider and Blackburn (59) who reported a novel
activity which added TTGGGGG repeats onto synthetic telomere primers in Tetrahymena
cell-free extracts. They proposed that terminal transferase was involved in the addition of
the telomeric repeats necessary for the replication of chromosomal ends in the eukaryotes.
Over the next few years these two workers and other colleagues set out to search for
telomerase in various species, including humans (57). They identified telomerase in many
single-cell organisms but, to their surprise; found that many human cells lacked the
enzyme. Greider, Harley and co-workers examined normal human somatic cells, however,
and then realised that they lost segments of their telomeres as they divided in culture, in
keeping with absence or inactivity of telomerase. The exception was germ line cells, in
which the telomeres remained intact and telomerase activity was detectable (25, 48).
29
Although reduction of telomere length and proliferative capacity suggests a major
involvement in human aging, it may not be the main factor. A different suspicion as to its
primary function, has been raised i.e. could the loss of proliferative capacity observed in
human cells lacking telomerase have endured not to age us but to help us to avoid cancer?
Indeed work has revealed that telomerase can be identified in most human cancer cell lines
and that, in contrast to most normal human cells, cancer cells can express telomerase,
retain their telomeres and have the potential to survive indefinitely (6). This is discussed
below (1.3.4.1).
The increasing interest in telomerase activity demanded the development of a specific,
sensitive and reliable method for its extraction and detection in tissues and cells. Such an
assay was first described by Kim and colleagues (63) and then refined by Piatyszek and co-
workers (64). In brief, the method was peR-based and used a single tube reaction in
which telomerase first synthesised extension products, followed by the use of these
products as templates for peR amplification. The refined method was designated the
TRAP (telomeric repeat amplification protocol) assay and shown to give high sensitivity
and a faster result.
Although it is a one tube peR-based protocol, it is performed in two steps: (1) telomerase-
mediated extension of an oligonucleotide primer (TS) which serves as a substrate for
telomerase and (2) hot start peR amplification of the resultant product (an incremental 6-
nucleotide single-stranded DNA ladder) with the oligonucleotide primer pair, TS (forward)
and ex (reverse). The oligonucleotides were designed to minimise primer-dimer artefacts.
Extraction is by a gentle detergent-based lysis. The TRAP assay has been of inestimable
help in measuring telomerase activity in various tissues, acting as a significant "marker".
In future this may be of diagnostic and prognostic value, including in therapy where the
presence of telomerase could be established before therapeutic inhibition by anti-
telomerase is used (see figure 1.9)
Figure 1.9 Diagram of the TRAP assay
In the first step tissue or cell extracts to be tested are incubated with an end-labelled
oligonucleotide (TS Primer) for 30 minutes at 30°C. If telomerase activity is present in the
extracts then TTAGGG repeats will be added to the labelled primer. The second step is
PCR amplification of these extended products. These products can then be separated by
eletrophoresis on a polyacrylamide gel and the characteristic 6bp ladder is observed m
telomerase positive extracts.
Taken from Checkpoint controls and Cancer Vol2 2004 Page 335
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1.4.3 Structure
The active telomerase complex contains several protein components as well as an RNA
subunit, the catalytic component TERT (telomerase reverse transcriptase). The catalytic
subunit has been cloned from a variety of different species and is a specialised reverse
transcriptase (RT) that uses an associated RNA to provide a template for DNA telomeric
repeats (21). In humans it is now known as hTERT but it has also been called HTCS1,
hTRT, hTCS1, TP2 and hEST2. TERT proteins vary in size ranging from 103-134 kDa
and all share sequence motifs in common with conventional RTs, as well as unique
sequence features in keeping with their telomerase activity (45). Their polymerisation
activity is restricted to copying a short sequence of RNA template repeatedly, a function
made use of in the TRAP assay (64).
The intrinsic RNA component (TR, telomerase RNA) is associated with several protein
components as well as TERT (65). All TRs contain a characteristic sequence
complementary to one unit of the telomeric repeat. Over 30 TRs have been cloned varying
in size from 159 nucleotides in Tetrahymena to 1300 nucleotides in yeast. Human and
mouse TR are about 400 nucleotides in length. TRs show low sequence homology but
share a conserved secondary structure consisting of a stem, a pseudo-knot and a set of
stem-loop structures.
In addition to the TERT and TR which form the catalytic core of telomerase, several other
proteins have been identified in different species (45). These lack structural and primary
sequence conservation. For instance, TP1 in mouse and human are dissimilar to TLP1 in
rat which is a large protein (230-240 k Da) binding TR. TP1/TLP1 is also a component of
vaults, ubiquitous cytoplasmic ribonucleoprotein particles of unknown function. Indeed,
the function of the telomerase-associated proteins is not known but they probably act to
regulate its activity. Chaperones p23 and hsp90 also associate with the human telomerase
complex by binding to TERT: and in vitro and in vivo studies reveal that their role is
essential in assembling active telomerase in humans.
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1.4.4 Function
It appears that telomerase is expressed routinely by cells of the germ line in the developing
embryo. Once cell differentiation occurs in the body, however, telomerase is repressed in
many somatic cells with resultant telomere shortening. When telomeres reach a critical
length, the uncapped telomere is thought to provide a signal which stops further replication
and then the cell becomes senescent. It has been demonstrated that if telornerase is
switched on in senescent cells then the cell can elongate its telomeres and re-enter the cell
cycle and proliferate (66, 67).
If, however, cancer-promoting genetic mutations have occurred which block the danger
signal, cells will bypass senescence and continue to divide (6). These cells will also
presumably continue to lose telomeric sequences and undergo chromosomal changes
which may allow further carcinogenic mutations to arise. However as the telomeres reach
criticall y short lengths the cells will reach a point at which crisis occurs and they die. If,
however, in the precrisis period cells can activate telomerase, the cells will maintain their
telomeres: they will be kept, albeit shortened, and although genetically disturbed will
continue to replicate showing the immortality characteristic of cancer (other features are
discussed below).
Apart from germ cells and most malignant tumours, low telomerase activity is found in
some normal somatic cells including stem cells in renewable tissues, e.g. intestinal crypts
and the basal layer of the skin, haematopoietic tissues and activated lymphocytes (68). The
telomerase activity is low and, although it provides for an increase in proliferative
capacity, it still does not prevent telomere shortening. In contrast to human tissues,
significant telomerase activity is present in most normal mouse tissues suggesting different
regulatory mechanisms (45).
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1.4.5 Telomerase knockout mouse
Different species, like different cell types, have varying lengths of telomeres. Mice have
telomeres which are three times longer than human telomeres. For this reason the
generation of a telomerase knockout mouse was a great achievement (69-72). First the
knockout mouse lacking the RNA component of telomerase was created and then it was
allowed to reproduce for six generations until short telomeres were achieved. This animal
model supports the telomere hypothesis: It has an aged phenotype, there is an increase in
grey hairs, skin lesions and alopecia with decreased body mass, impaired wound healing,
infertility, abnormalities in the gastrointestinal tract and defects in the haematopoietic
system.
1.4.6 Role of telomerase in certain diseases
Telomerase activity has been studied in various human diseases i.e. in several types of
malignancy, especially colorectal carcinoma (73); in cirrhosis of the liver, where there is
severe tissue damage accompanied by continuous regeneration (74); in AIDS (75) and in
rare diseases like dyskeratosis congenita where the telomeres are abnormally short (76, 77)
1.4.6.1 Neoplasia
Telomerase activity is found in 95% of all malignant tumours (57) but it is very important
to realise that this is not what makes normal cells malignant. Telomerase expression only
allows the cells to grow indefinitely: the transformation to malignancy has already
occurred. Expression of telomerase may, however, contribute to the severity and outcome
of the disease since it allows mutated cells to continue dividing and accumulate more
genetic abnormalities including those leading to metastatic growth and angiogenesis, in
other words, adding to the malignant features of the original tumour (50, 73, 78). The
high incidence of telomerase expression in cancer has promoted the idea of using anti-
telomerase therapy. Since most normal somatic tissues do not express telomerase,
inhibiting telomerase may provide a strategy for the treatment of cancer (79-81).
1.4.6.2 Cirrhosis of the liver
Cirrhosis of the liver affects several hundred million people every year. The main causes
of the disease are chronic viral hepatitis, followed by alcoholism. Damaged liver will
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regenerate to a degree but fibrous scarring and architectural distortion set in. Once the
normal anatomy is badly disrupted liver failure ensues. At this point the only hope for a
patient is a liver transplant. As would be expected, the length of telomeres in the cirrhotic
liver is much shorter than those in a healthy individual (82). To test whether or not this
feature was contributing to the disease state, an experiment was carried out using
telomerase knockout mice (82, 83). Cirrhosis was induced in animals by one of three
mechanisms: chemicals, surgical damage or due to a genetic disorder. This was achieved
by subjecting mice to repeated exposure to hepatoxins such as CCI4, or removing two
thirds of the liver or using a genetically engineered mouse, an albumin-directed urokinase
plasminogen activator (Alb-uPA) mutant. Alb-uP expression has been shown to cause
widespread death of hepatocytes and liver failure in new-born mice. It was found that,
compared to controls, the mTR-/- mice had a more severe phenotype of the disease and
could not reconstitute the liver effectively. To verify that cirrhosis in each case was in fact
due to the lack of telomerase and short telomeres, the mice were infected with an
adenovirus containing mTR. The mice with short dysfunctional telomeres now had
telomerase activity and telomere function: the damage to the liver was reversed, liver
function improved and disease progression slowed.
1.4.6.3 Dyskeratosis congenlta
Dyskeratosis congenita (DKC) is a very rare genetic disorder characterised by
abnormalities in skin pigmentation, nail growth, learning difficulties, pulmonary disease,
greying and hair loss. There are also abnormalities of the gastrointestinal tract,
hypogonadism, osteoporosis and an increase in epithelial and haematologicaI cancers.
Death usually occurs by the age of 16 years, although there have been cases of patients
living until 50 years old (76). DKC is caused by a genetic defect which results in the
absence of a protein called dyskerin. Dyskerin is expressed ubiquitously and thought to
function in the formation of ribosomes in the nucleolus, as well as leading to reduction in
levels of hTERT, the RNA template of telomerase. As a result of the latter, sufferers from
DKC have abnormally short telomeres explaining why the disease shows characteristics of
advanced aging. Death is usually due to bone marrow failure or malignancy. This
disorder highlights the importance of telomere length in the replicative lifespan of cells in
normal development (77).
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1.4.7 The telomerase catalytic subunit (TERT) and reconstitution
of telomerase activity
Cloning of the mouse telomerase component was reported in 1997(84, 85). A mouse
genomic TERT was identified by hybridisation to a 450-nucleotide (nt) probe from the
transcribed region of the human telomerase RNA gene. (This region was 65% homologous
with the human RNA gene) (61, 84, 85).
Isolation and characterisation of the catalytic subunit of mouse telomerase or TERT
(mouse telomerase reverse transcriptase) an essential component of the telomerase
complex, was reported in 1997 (85,86).
Studies soon showed that reconstitution of telomerase activity could be achieved in normal
human cells (66, 67, 87). Retroviral-mediated expression of hTERT resulted in functional
telomerase activity in normal aging human cells. In addition, when reconstruction was
achieved in vivo, elongation in telomeric DNA was identified and cellular lifespan was
shown to be increased. Of the greatest importance, transfection of hTERT into normal cells
was shown not to lead to malignant transformation.
Bodnar et al (67) transfected skin fibroblasts and retinal pigment epithelial cells also, with
vectors encoding the human telomerase catalytic subunit. In contrast to telomerase-
negative control clones which exhibited telomere shortening and cell senescence,
telomerase-expressing clones had elongated telomeres, continued to divide and showed
reduced staining for ~-galactosidase (a marker for senescence). Their karyotype was
normal and they exceeded their expected lifespan by at least 20 doublings. Again the
workers categorically stated that normal human cells were maintained in a "phenotypically
youthful state", and they outlined the important applications this could have for research.
Expression of the human telomerase catalytic component hTERT in normal human somatic
cells can reconstitute telomerase activity and extend their replicative potential. Jiang and
colleagues (88) showed that, at twice the normal life span, telomerase-expressing human
skin fibroblasts (BJ-hTERT) and retinal pigment epithelial cells (RPE-hTERT) retained
normal growth control in response to serum deprivation, high cell density, 01 or 02 phase
blockers and spindle inhibitors. No cell growth was observed in soft agar and no tumour
formation in vivo. Thus it was concluded that telomerase expression in normal cells does
not appear to induce changes associated with a malignant phenotype. However, it has
recently been shown that if cells are allowed to grow in vitro for 150 MPDS, it can lead to
37
the production of a selective neoplastic variant (89). A cell in culture for this length of time
results in expanding a cell population by 1016, this is far greater than would ever be
required.
1.5 Skeletal muscle
Skeletal muscle is the major tissue in the human body. It consists of long, striated (striped)
fibres attached to the skeleton by tendons, usually under voluntary control. The main
muscle groups form the pelvic and shoulder girdles, the limb muscles and those of the axial
skeleton.
1.5. 1Anatomy
Muscle fibres are composed of multinucleate cells up to 10 cm or more in length with
diameters ranging from 10 to 100 urn. They run from one end of the muscle to the other
and are polygonal in shape. The main structural features are shown in figure 1.10.
The multinucleated individual muscle fibres are surrounded by a cell membrane, the
sarcolemma or sarcolemmal membrane, which actually consists of two layers: a plasma
membrane attached to the muscle cytoplasm or sarcoplasm (the plasma-lemma) and an
outer basement membrane (basal lamina). Between the two layers lie the nuclei of the
satellite cells, the cells with proliferative potential (see figure 1.10b and 1.11).
Up to 90% of the volume of the muscle fibre is composed of the contractile elements, the
myofibrils. These have a mean diameter of 1 urn and are composed of myofilaments (see
figure 1.10c) and thin actin filaments. Together they form the contractile elements of the
fibre and, in series, in regular sequence are known as the sarcomere (33, 90, 91).
Figure 1.10 The structure of skeletal muscle, illustrating the appearance and
organisation.
A. Gross anatomy of skeletal muscle. The muscle is attached to the bone via a tendon and
deep fascia. The skeletal muscle consists of 3 layers of connective tissue, an outer
epimysium, a central perimysium and an inner endomysium. The perimysium divides the
skeletal muscle into a series of compartments which contain the fascicles, the bundles of
muscle fibres.
B Diagram of an individual fascicle. Within the fascicle the endomysium surrounds each
fibre and attaches fibres to one another. Stem cells are scattered among the fibres to repair
any damage.
C. Diagram of the skeletal muscle myofibrils showing a detailed electron micrograph
through a skeletal muscle cell. The regular cross striations can be seen. Below is a
schematic representation of the single sarcomere showing the interaction between the light
and dark bands, and the Z disc and M line.
Adapted from Molecular Biology of the Cell, Alberts B, Bray D, Lewis J, RaffM, Roberts
K, Watson, J.D, Third Edition p853
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Figure 1.10 The structure of skeletal muscle, illustrating the appearance and
organisation.
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1.5.2 Function
Apart from the usual organelles (mitochondria, Golgi apparatus etc.) the sarcoplasm
contains two specialised internal membrane systems: The transverse (T) tubular system,
consisting of invaginations of the surface membrane into the fibre and the sarcoplasmic
reticulum which is in close contact with it and forms lateral sacs or terminal cisternae at
the surface of the myofibril (see figure 1.11). These two interconnected systems are
concerned with the excitation of muscle during contraction and relaxation. The "sliding
filament" theory describes muscle action (92): an electrical impulse travels down the
nerve and reaches the terminal cisternae of the sarcoplasmic reticulum, via the T system.
Calcium is released and bindings to troponin on the thin filaments which changes its shape
to uncover cross bridging sites on actin. These bind to myosin which has been energised by
splitting ATP into ADP + P + energy, by myosin ATPase. The crossbridge bends
producing a power stroke which pulls the thin filament inward, shortening the muscle
sarcomere i.e. contraction occurs (see figure 1.12).
Figure 1.11 T tubules and the sarcoplasmic reticulum
A. Schematic of the two systems of membranes which relay the signal to contract from the
muscle plasma membrane to all of the myofibrils in the cell.
B.Electron micrograph showing two T tubules.
Adapted from Molecular Biology of the Cell, Alberts B, Bray D, Lewis J, RaffM, Roberts
K, Watson, J.D, Third Edition p853
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Figure 1.11 T tubules and the sarcoplasmic reticulum
Figure 1.12 The cycle of crossbridging during muscle contraction
A Attached. At the start of the cycle the myosin head is bound tightly to the actin filament.
This is terminated by the binding of ATP to the myosin head
B Released. The ATP molecule binds to the back of the head of the myosin and this result
in a change in conformation of the head, allowing it to move along the filament.
C Cocked. The cleft closes around the ATP molecule resulting in the head being displaced
approximately 5nm along the filament. Hydrolysis of ATP occurs but the ADP and
inorganic phosphate (Pi) remain attached to the head.
D Force-generating. The weak binding of the actin to the myosin head causes the release of
the Pi, resulting in the bond strengthening. The myosin head is now attached to a new actin
site. The release of the Pi results in the power stroke and during this ADP is lost and the
myosin head regains its initial conformation.
E Attached. At the end of the cycle the myosin head is again tightly locked to the actin
filament in its new position.
Adapted from Rayment 1. Structure of the actin-myosin complex and its implications for
muscle contraction. Science. (1993) 261; 5117: p 58-65.
ATTACHED
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Figure 1.12 The cycle of crossbridging during muscle contraction
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1.5.3 Satellite cells
Muscle has a limited proliferative ability dependent on the function of the "satellite" cells
(93) These, as stated above, lie between the plasma and basement membranes, usually
adjacent to peripheral myonuclei, They have nuclei with dense peripheral heterochromatin
and a small amount of cytoplasm with a few organelles but no contractile myofilaments.
They are usually in the GOphase of the cell cycle but can leave it to enter the mitotic cycle
and differentiate to express muscle-specific proteins. Their activation and differentiation is
tightly regulated by myogenic regulatory factors of the MyoD family and the cyclin-
dependent kinases and their inhibitors (94). These are in tum controlled by growth factors.
Satellite cells are obviously key players in muscle fibre growth, regeneration and
hypertrophy. There is evidence that they are a heterogeneous cell population in terms of
mitotic cycle duration and ability to differentiate.
The numbers of muscle fibres do not increase postnatally and growth occurs by fibre
enlargement so that the contribution of satellite cells is critical. There is evidence of age-
related alterations with the average number of progeny produced inversely proportional to
donor age. Satellite cells from old rats initiate DNA replication more slowly in vitro than
cells from young or foetal rats and divide less frequently. In vivo the number of satellite
cells in mouse soleus muscle drops from 4.6% at 8 months of age to 2.4% at 30 months.
Various growth factors have been described as having an effect in culture Le. basic
fibroblast growth factor, insulin-like growth factor, platelet-derived growth factor and
transforming growth factor (95).
The process of satellite cell differentiation includes withdrawal from the cell cycle,
expression of muscle-specific markers and fusion with one another to form myotubes or
with existing myotubes or myofibres. Differentiation is accompanied by decreased
apoptosis.
The muscle specific proteins are expressed at specific stages of muscle development ( see
figure 1.13) (94). The first ones appear before withdrawal from the cell cycle: Le. desmin,
the muscle-specific intermediate filament protein, is seen first. The myogenic transcription
factors of the MyoD family, including MyoD, MRF, myf-5 and myogenin are then
expressed in order (96). MyoD is the first to appear and marks the onset of terminal
myoblast differentiation. Myogenin is the last to appear. Expression of these factors is
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followed by cell cycle arrest, then phenotypic differentiation and then cell fusion. As will
be seen, satellite cells playa crucial role in DMD.
1.6 Duchenne Muscular Dystrophy
Duchenne muscular dystrophy (DMD) is the most common and most severe of a group of
inherited disorders characterised by chronic, progressive muscle wasting and degeneration
(97, 98). It is the second most common genetic disorder, affecting 1 in every 3,500 live
male births. It leads to a wheelchair existence at the end of the first decade of life and death
from cardiac and respiratory failure by the end of the third.
Anatomists in the early 19th century first studied selective involvement of various muscle
groups in disease (99). The clinical and pathological features of DMD were described in
the mid 19th century, due to the work of the English physician Edward Meryon (1807-
1880) and the French physician, Duchenne (1806-1875). Meryon (1851) first described the
systemic clinical and pathological findings in the disease, reporting four families with a
large number of affected males. He reported the progressive muscle weakness and wasting,
beginning in early childhood and leading to premature death. He also stressed the fact that
it had a predilection for males and was frequently familial. He identified the disease as a
primary muscle disorder and showed on microscopy that, unlike other cases of what was
termed "muscular paralysis", the spinal cord and nerves were completely normal while the
muscle was replaced with adipose and fibrous tissue.
Concepts of genetics were poorly understood at the time. Although Mendel had published
his work in 1866 it was not known to the scientific community until 1900 (100). The
similarity between the inheritance of DMD and haemophilia apparently did not strike
Meryon although the latter was very well known, and he described cases of DMD simply
as familial.
Twelve years after publishing his initial report, Meryon expanded his observations on
DMD to form a chapter in his book (101) but it was the French physician, Duchenne de
Boulogne who made personal and extensive observations on DMD. He produced excellent
photographs of his cases, reported electrophysiological results derived from the apparatus
he had constructed and biopsy fmdings using the muscle biopsy needle which he made. It
is his name which is now attached to the disease
47
Duchenne believed that Meryon, with whose work he was familiar, was describing a
different disease (progressive muscular atrophy) although Meryon refuted this in his 1864
book. Indeed, Meryon must be regarded as having more insight into the pathogenesis of
DMD because he described it as a primary muscle disorder characterised by what he
described as "granular degeneration" of fibres whereas Duchenne thought that the
abnormality was in the nervous system and the muscle showed simply hyperplasia of the
fibrous and fatty tissue: an effect which is secondary (102).
DMD, and its allelic, less severe variant, Becker's muscular dystrophy (BMD) has
attracted intense interest since it was first described and the landmarks in its study are
summarised in the Table 1.1 (98).
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Figure 1.13 Sequence at which muscle specific proteins are expressed
Demonstrates when specific muscle proteins are expressed
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Table 1.1 Landmarks in the history of Duchenne and Becker muscular
dystrophies taken from The History of a Genetic Disease, Emery & Emery.
1830- Muscular dystrophy recognised as a disorder and DMD as a
specific type of dystrophy
1860-1900 Microscopic myopathology defined
1930-1960 Resolution of heterogeneity by clinical and discriminant
analysis BMD defined (1955)
X-linked inheritance confirmed by segregation analysis (1959
1959-1960 Serum creatine kinase for diagnosis and carrier detection
1966-1968 Introduction of Bayesian statistics for risk estimation
1975-1980 Defect localised to muscle and other membranes by electron
microscopy and biochemistry
1979-1982 Gene localised to Xp21 Linked RFLP identified (1982)
1983-1984 DMD and BMD shown to be allelic
1983-1985 Linked RFLPs first used for carrier detection (1983), and
prenatal diagnosis (1985)
1985 Responsible gene isolated (gene-specific probes)
1987 Gene product (dystrophin) identified
1988 Dystrophin localised to sarcolemma, absent in DMD and
abnormal in BMD
1989 Myoblast transfer in mdx mouse
1990 Gene therapy in mdx mouse
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1.6. 1 Pathogenesis
If dystrophin is absent, muscle tears when it contracts. Before the child with DMD shows
clinical symptoms, muscle biopsy reveals large, hypercontracted, eosinophilic and
prenecrotic fibres which have arisen because calcium enters the fibre through the
sarcolemmal defect. This leads to mitochondrial overload and fibre death and then more
muscle damage due to activation of proteases. Engel et al (103) provided the seminal work
showing that the sarcolemmal membrane was indeed defective in the prenecrotic fibres and
that this was the primary lesion in DMD. Their ultrastructural studies showed focal
disruption or absence of the plasma membrane while the basement membrane was
preserved.
Muscle biopsy from a case of DMD will reveal complete absence of dystrophin. The
disease was later discovered to be caused by a mutation in the dystrophin gene (104). In
BMD, the protein expressed seems to be partially functional, explaining the differences in
severity of the two diseases (105). In both diseases, fibre necrosis is followed by
regeneration. Regeneration ceases at a certain time, however, and the muscle tissue is
replaced with fibrous and fatty tissue.
1.6.2 Clinical features
At birth, the baby appears normal but the parents note that he is slow to walk. The child
then gradually develops the characteristic calf enlargement (hypertrophy) and has difficulty
in climbing stairs. He starts to show Gower's manoeuvre (see Figl.14) Le. in a sitting
position he raises himself by climbing up along his own legs. By the early teens, muscle
wasting is such that the child is in a wheelchair permanently. The disease is fatal by the
late twenties or early thirties due to respiratory or heart failure. In very few cases DMD is
associated with mental retardation (106).
The muscles most severely affected are those of the pelvic and shoulder girdles, the
proximal upper and lower limbs and the trunk muscles. The latter leads to exaggerated
lumbar lordosis and scoliosis. It is the pelvic and lower limb muscle involvement which is
responsible for the child demonstrating Gower's manoeuvre. Respiratory muscle
involvement is relatively late, beginning at the end of the second decade.
Figure 1.14 Schematic diagram of Gowers Manoeuvre
Demonstrates the ability of children with DMD to move from a seated position on the
floor, to standing position. The child first has to roll over on to all fours and then push
himself up with his hands. The child then walks inward and uses upper body strength to
regain an upright position.
Taken from W.R.Gowers' Pseudo-hypertrophic Muscular Parlaysis, 1879, Clinical sign for
the development of DMD Figure 1.14 Schematic diagram of Gowers Manoeuvre Figure
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Figure 1.14 Schematic diagram of Gowers Manoeuvre
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1.6.3 Pathology
The pathological features of DMD depend on continuous cycles of degeneration and
regeneration. This is due to the lack of dystrophin in the cell membrane which results in it
being weakened, therefore when the muscle contracts it tears (107). Segmental necrosis of
muscle fibres occurs in the late stage, resulting in only a few clusters of tiny and large
fibres remaining, all surrounded by adipose and fibrous tissue. Prenecrotic fibres can be
identified in the early stages when there is conspicuous evidence of regeneration (108). As
the disease progresses, the regenerating (satellite) cells with large nuclei, basophilic
cytoplasm and immunohistochemistry positively of N-CAM, HLA class 1 and MyoD,
become less and less common until they are completely absent (94). At this stage there is
no satellite cell multiplication and no muscle regeneration. Adipose and fibrous tissues
with scant clusters of fibres are all that remain.
The pathological picture, when seen with the clinical features, is almost diagnostic and
becomes complete when immunohistochemistry reveals the characteristic complete lack of
dystrophin. In BMD, the allelic variant of DMD, dystrophin is present but fragmented and
in variable amount.
1.6.4 Inheritance
The disease is passed from mother to son (figure 1.15). The mother herself is unaffected
because she has one normal dystrophin gene (90). If the mutation is passed to her daughter,
she is unaffected also but, like her mother, is a "carrier". Very rarely a carrier has muscle
problems in which case she is known as "manifesting carrier". This occurs when the
normally random inactivation of the X chromosome is biased. Extremely rare cases of
female patients with typical DMD have been reported. This occurs when an X autosomal
translocation has occurred.
In two-thirds of cases there is a family history of an affected uncle or brother. In one-third,
however, a new mutation has occurred in the massive dystrophin gene (109). Thus genetic
counselling cannot eliminate this disorder.
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Figure 1.15 Pattern of inheritance
Figure demonstrates how the defective gene is passed from mother to son resulting in the
disease, and from mother to daughter resulting in the daughter becoming a carrier.
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1.6.5 Dystrophin gene
The dystrophin gene was discovered in 1986, located at Xp21.1 (110, 111). It is the largest
gene known at 2.4mB with 79 exons, of mean size 0.2 kB, and introns of mean size 35 kB
(see figure 1.16). The actual coding sequence represents less than 1% of its nucleotide
composition which is transcribed into a 14kB DNA. It is probably the large size of the
gene which makes it liable to the effect of mutagenic agents and accounts for the relatively
high mutation rate of around 1 in 10,000 male births. The site and type of mutation are
important. Deletions affecting the central rod domain are more likely to lead to a milder
BMD phenotype whereas those affecting the C-terminal result in DMD. The gene takes up
to 24 hours to be transcribed and forms about 0.1% of the total human genome. It shows
strong homology to utrophin and spectrin, contains multiple promoters and has six
alternative sliced exons in the C-terminal domain. In 65% of the cases of DMD, the
mutation is due to a deletion or duplication, while 5% of cases arise from duplication; the
remaining 30% have point mutations. In all cases of DMD the reading frame is lost and
this leads to premature termination of translation. In BMD, the less severe variant, the
reading frame is not lost and a truncated form of the protein is produced (112).
Figure 1.16 Dystrophin gene
A: Genomic organisation of the dystrophin gene, located in Xp21. The black vertical lines
represent the 79 exons of the dystrophin gene distributed over about 2·S million bases. The
arrows indicate the various promoters: in particular brain (B), muscle (M), and purkinje (P)
promoters; R, B3, S, and G represent the Dp260 (retinal), Dp140 (brain.), Dp116 (schwann
cells), and Dp71 (general) promoters. B: The domain composition of the various
dystrophin proteins is indicated. The amino-terminal domain is followed by the spectrin-
like domain, the cysteine-rich, and the carboxy-terminal, domains.
Taken from Muntoni F., Dystrophin and mutations: one gene, several proteins, multiple
phenotypes, Lancet Neurology, 2003, 2; 12: p 731 - 740
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Figure 1.16 Oystrophin gene
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1.6.6 Dystrophin protein
The major site of expression of dystrophin is at the inner surface of the sarcolemma of
skeletal muscle. Full length transcripts can also be found in the brain and purkinje cells but
in much lower abundance. The dystrophin gene contains multiple promoters and shorter
transcripts are found in the retina, brain, kidney, schwann cells and in most non-muscle
tissue (see figure 1.16). Dystrophin is a 427 kDa protein which can be divided into four
domains: an N-terminal actin domain (240 amino acids) a rod-shaped triple-helical
spectrin-like domain (3000 amino acids), an a-actin-like cysteine rich domain (280 amino
acids) and a unique C-terminal domain (420 amino acids) (113, 114). In muscle, its role is
as a link between the actin-associated cytoskeleton and the dystrophin glycoprotein
complex (DGC) (see figure1.17) (115). It forms 0.002% of muscle protein.
1.6.7 Dystrophin glycoprotein complex
Dystrophin is not directly attached to the sarcolemmal membrane but interacts through a
complex of glycoproteins, the DGC (figure 1.17) (116, 117). The DGC can be divided into
3 domains, extracellular (lamin and a-dystroglan), transmembrane (J3-dystroglyan and
sarcoglycan proteins) and submembrane (dystrophin, utrophin, dystrobrevins and the
syntrophins). J3dystroglycan spans the sarcolemmal membrane binding at its extracellular
end to the a-dystroglycan and at the intracellular, to the C-terminal of dystrophin. a-
dystroglycan then links to the extracellular matrix component, laminin. Thus, there is a
network of interactive proteins providing a link from the intracellular contracting muscle
fibre to the extracellular matrix (see figure1.17).
The submembrane domain of DGC, the dystrobrevins and syntrophin, act to bring assorted
components of the DGC together by interaction amongst themselves and dystrophin. In
DMD, there is an absence or reduction in all the components of DGC while in BMD, this
is seen to a lesser degree. Individual components have now been shown to be absent in
certain other inherited muscle disorder diseases.
Figure 1.17 The dystrophin glycoprotein complex
Shows the relationship between the dystrophin protein and the structure of the muscle
complex. When the muscle contracts, dystrophin anchors the actin fibre to the sarcolemma
via the complex.
Adapted from Roush.W, Muscular Dystrophy: Backup gene may help muscles help
themselves. Science (1997); 276: 5309 p35
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Figure 1.17 The dystrophin glycoprotein complex
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1.6.8 Satellite cells in DldD
Almost all the muscles in the affected boy consist finally of a few muscle fibres of varying
size, surrounded by fat and fibrous tissue. Before this occurs, several workers have
reported increased numbers of satellite cells (Se) compared to controls (94). In the first
two to three years of life, regeneration keeps pace with fibre destruction but as the disease
progresses there is more and more evidence of inadequate replacement.
Satellite cells are the only muscle cells which replicate; they form approximately 5-6% of
the total muscle nuclei in the adult (95). Satellite cell replicative capacity is diminished in
DMD (94). The normal age-related decline has been shown to be accelerated in DMD
myoblasts: (118). The average myoblast from a 5 year old healthy boy is capable of 56
doublings or a potential yield of 1017 cells but in patients with DMD as young as 2 years
(the typical age of clinical onset) only 6% of myoblasts were found to be capable of 50
daub lings and by the age of seven, only rare myoblasts could achieve even 10 divisions.
Study of telomere length provides an indication of how many cell divisions a cell has
undergone, and, once the normal number of mean population doublings (MPDs) is known,
what regenerative capacity remains. The rate of telomere shortening in myonuclei from
skeletal muscle satellite cells at ages from 5 days to 86 years has been established:
replicative capacity and telomere length decrease in parallel with age for the first two years
of life but then remain remarkably stable with a regular loss of telomere sequences of 75-
155 bp per cell division. In boys with DMD there is a marked decrease in satellite cell
telomere length by the age of 2 years: as early as this, telomere loss is 14 times greater than
in satellite cells from healthy two year olds (119) (187 bp/year versus 13 bp/year).
However there is some controversy surrounding this as other groups have suggested that
replicative senescence has no role in DMD, and the telomeres remain at a normal length
(120) This group has suggested that it is the lack of differentiation in DMD which results
in onset of the phenotype, not failure to replicate. It is difficult to determine which group is
correct. However discrepancy may be due to the insensitive nature of southern blotting.
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1.6.9 Animal models
Naturally occurring and experimental laboratory models of DMD are available, with the
latter being much more frequently used.
1.6.9.1 Xmd golden retriever and cats
A naturally occurring animal model for DMD is seen in the golden retriever dog (121). It
shows the phenotype of the disease before the age of one year with stiff hind legs and
progressive muscle wasting. This model has the closest clinical resemblance to the human
disease. The pathological picture is also similar and immunohistochemistry confirms the
absence of dystrophin. Ethical approval for working with canines can however prove
difficult. There are also reported natural cases of felines with DMD which, like the canine
model resemble the human disease more closely than that in the mdx mouse. These are
rarel y used in research.
1.6.9.2 The mdx mouse
Currently the most popular animal model for DMD is the mdx mouse. The mouse model
was first introduced by Bulfield et al, in 1984 (122) as a murine glycolytic mutation with
histological evidence of myopathy. The mdx mouse has a premature stop codon in exon 23
of the dystrophin gene. It has no detectable levels of dystrophin, although it has been
reported that dystrophin can be seen in revertant fibres. No dystrophin is present during
immunoblotting, but some fibres are positive for dystrophin under fluorescent microscopy.
On further analysis, it was shown that they were expressing dystrophin despite the
mutation in the gene (123). The mdx mouse does not show the phenotypic wasting seen in
the human disorder, however it has been reported that the limb muscles of the mdx mouse
are susceptible to injury and this increases with age (124).
This model has been used extensively in the development of new therapies for DMD.
1.6.10 Current therapies for DMD
At present the treatment of DMD and BMD is purely supportive directed at maintaining a
better standard of life for the patient but providing no cure for the disease. The main
medication used is steroid therapy which may help to protect the necrotic muscle. The
other options are mainly orthopaedic procedures. Trunk deformities like scoliosis appear,
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especially when a wheelchair is required. This causes respiratory problems and to
counteract this, a steel pole may be fused with the spine to straighten it. The patient can
then sit in an upright position so that the onset of respiratory failure may be postponed for
a number of years. Another therapy is the use of oxygen in the home. In the latter stages of
the disease the children often suffer from sleep apnoea. By allowing the child to breath
pure oxygen, he can obtain a full night's sleep. It has been shown that this can greatly
improve in the child's standard of life. Also very important in the treatment of this disorder
is the role of physical therapy. This helps to prevent the onset of contractures. Because this
is a hereditary disease genetic screening for families at risk and genetic counselling is an
important aspect of the treatment (125).
Due to the nature of this disorder, there is at present no therapeutic cure, and it is unlikely
there will be. However there is extensive research being performed in the development of
gene therapy or cell therapy to aid this disorder but, as of yet, these have been unsuccessful
in clinical trials. These will be discussed in more detail in the discussion.
1.7Aims
This disease would appear to be an ideal candidate for gene therapy, but this has not yet
been achieved. The constant necrosis and regeneration of the muscle cells in these children
result in the lack of replicative capacity. We feel this may playa major role in the problem.
Therefore the aim of this project was to assess if it was possible to immortalise normal
human muscle cells by transfection with hTERT alone. The muscle cell lines produced
would then be tested to assure that they had not adapted a malignant phenotype using cell
culture techniques and karyotyping. This is important as the immortalisation had to be
achieved without inducing malignant transformation. Previous attempts using hTERT
alone had been unsuccessful. If the experiments were successful, we would then
investigate how our technique had differed from others. The cell lines would be further
characterised to asses how the introduction of telomerase had changed there cell cycle
properties by examining the cell cycle regulators. Finally the differentiation capacity of
these cells line would be explored in culture and in an animal model. If successful this
suggests a way of producing long-lived cell lines for research and hopefully for cell
therapy in the future.
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Chapter 2 Materials and Methods
2. 1 Materials
General cell culture media and supplies
Supplier Reagent
NSNunc
Botolph Claydon,
UK
1ml Cryotubes
Sigma Chemical Company
Fancy Road,
Poole,
Dorset,
UK
Penicillin G (benzylpenicillin)
sodium salt,
Cat No. P3032
Streptomycin Sulphate BP,
Cat No. S9137
Becton Dickinson Labware
Plymouth,
UK
Falcon tissue culture dishes,
full range
Fisher Scientific UK
Bishop Meadow Road,
Leicestershire,
Loughborough,
UK
LE115RG
Dimethylsulfoxide
(CH3.SO.CH3)
Cat No. BPE231-1
Gibco BRL Life Techologies
Paisley,
UK
DMEM,
Cat No. 21969-035
HEPES Buffer,
Cat No. 15630-056
L-Glutamine,
Cat No. 25030-032
Geneticin (G418 Sulphate)
Cat No. 11811-098
Worthington Biochemical
Corporation, Reading, UK
Autogen Bioclear
Trypsin,
Cat No 39J3128
Fetal Bovine Serum
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Holly Ditch Farm,
Mile Elm, Calne,
Wiltshire,
UK
Cat No SOlIS
Horse serum
Cat No 7.10
Specialized Cell Culture Techniques
Supplier Reagents
Costar
Bucks,
UK
5mm filter membrane
Nalge Nunc International Corp
2000 North Aurora Road,
Naperville.IL,
60563-1796
USA
8 Well Permanox ® Slide,
Cat No. 177445
Sigma Chemical Company
Fancy Road,
Poole,
Dorset,
UK
Ploybrene (Hexadimethrine),
Cat No H9268
Hoeschst 33258
Cat No. BlISS
Puromycin dihydrochloride
Cat No.P8833
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Molecular Biology Kits
Supplier
QIAGENLtd
Boundary Court,
Gatwick Road,
Crawley,
West Sussex,
RH102AX
UK
Plasmid Midi Kit
Cat No 12143
Antibodies
Supplier Reagent
Vector Laboratories Inc
16 Wulfic Square,
Bretton,
Peterborough,
PE38RF
UK
DAB Substrate kit for peroxidase,
3,3' -diaminobenzidine
Cat No SK-4100
Vectashield with DAPI,
Cat. No. H-1200
Vectastain ABC Kit (Mouse IgG)
Cat. No. PK-4001
Vector MOM basic kit
Cat. No. BMK-2202
Novo Castra
Balliol Park West,
Benton Lane,
Newcastle upon Tyne,
NE128EW
UK
Spectrin Ab (Broad Spectrin).
Mouse Monoclocal,
Cat No. NCL-SPEC2
Spectrin Ab,
Mouse Monoclonal,
Cat No. NCL-SPEC1
DAKO
6392 Via Real,
Carpiteria,
CA,
USA
DesminAb,
Mouse Monoclonal,
Cat No. D33
Boehringer Mannhiem UK
(Diagnostics & Biochemicals) Ltd
Bell Lane,
Lewes,
East Sussex,
BN71LG
UK
Santa Cruz
Autogen Bioclear
Holly Ditch Farm,
Mile Elm, Calne, Wiltshire, UK
Western Blot
Supplier
Sigma Chemical Company
Fancy Road,
Poole,
Dorset,
UK
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5-Bromo- 2-deoxy- uridine
Labelling and Detection Kit 1,
Cat No 1296 736
p16 antibody
Mouse monoclonal,
Cat No. sc-9968
Reagent
Aprotin,
Cat No. A6279
Leupeptin,
Cat No. L2023
Pepstatin A,
Cat No. P4265
PMSF,
Cat No. P7626
Sodium Fluoride,
Cat No. S1504
Okadaic Acid,
Cat No. 07760
DTT,
Cat No. D0632
Benzarnidine,
Cat No. B6506
EGTA,
Cat No. E4378
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Chemicals
Supplier Reagent
Agar Sceintific Ltd
66a Cambridge Road,
Stanstead,
Essex,
CM24BDA
Paraformaldehyde
«CH20)nH-OH)
Cat No. Rl018
Amersham International
Little Chalfont,
UK
Redivue [u32p]dCTP"",3000Ci/mmol
Cat No. AAOOO5
BioFine Ltd
London,
UK
X-Gal
James Burrough (F.A.D) Ltd
70 Eastways Industrial Park,
Witham,
Essex,
CM83YE
UK
Ethanol (C2HsOH)
Cat No. SIN 1170
Fisher Scientific UK
Bishop Meadow Road,
Loughborough,
Leicestershire,
LE115RG
UK
Magnesium Chloride
(MgCh.6H20)
Cat No. M/0600/53
Methanol (CH30H)
Cat No. BPEII05-1
Sodium Chloride (NaCI)
Cat No. BPE358-1
Sigma Chemical Company
Fancy Road,
Poole,
Dorset,
UK
Ethidium Bromide
Cat No. E1510
Giemsa's Stain
Cat No. GS500
Glacial Acetic Acid (C2H402)
Cat No. A6283
Mes (2-[N-Morpholino]
ethane sulfonic acide)
Cat No. M8250
Sigma Chemical Company
Fancy Road,
Poole,
Dorset,
UK
ec« Reagents
Supplier
PE Allied Biosystems
Warrington, Cheshire,
UK
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TEMED
(N,N,N,N- Tetramethyl-
ethylenediamine)
Cat No. T8l33
EDTA (Ethy lenediaminetetra-acetic
acid, ClOH14N208Na2.2H20)
Cat No. ED2SS
Potassium Ferrocyanide
(~Fe(CN)6.H20)
Cat No. P9387
Potassium Ferricyanide
(K3Fe(CN6»
Cat. No. P3667
Enzyme
AmpliTaq® DNA Polymerase
Cat No. N80l-0060
lOX PCR Buffer & MgCh
Solution
Cat No. N808-00l0
Laboratory Plasticware
Supplier
Becton Dickinson Labware
Plymouth,
UK
Bibby-Sterilin
Stone,
UK
Elkay
Galway,
Eire
Greiner Labortechnik
Stonehouse,
UK
Electrophoresis Gels
Supplier
Sigma Chemical Company
Fancy Road,
Poole,
Dorset,
UK
Whatman International
Maidstone,
UK
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Material
Falcon Tubes
5ml Bijous
5ml & 20ml Universals
Microcentrifuge tubes
Pipette tips
Filter pipette tips
Reagent
Kodak X-OMA T Film
Cat No. F5263
3mm Chromatography paper
Cat No. 3030917
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Microbial Host, Media and Supplies
Supplier Material
Difoc
Central Avenue,
West Molesey,
Surrey,
KT82SE
UK
Tryptone, Bacto
Cat No. 0123-15
Yeast Extract, Bacto
Cat No. 0127-15
Bibby-Sterilin
Stone,UK
Petri dishes
Gibco BRL Life Techologies
Paisley,UK
Library Efficiency DH5a ™
Competent Cells
Cat No. 18263-012
S.O.C. Medium
Cat No. 15544-018
Sigma Chemical Company
Fancy Road,
Poole,
Dorset, UK
Ampicillin
Cat No. A9393
Cell Lines
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Plasm ids
pBabest2 and pBabe Neo retroviral plasmids were obtained from H. Vaziri and
S.Benchimol, Standford University School of Medicine, Department of Molecular
Pharmacology, Edwards Building, 300 Pasteur Drive Standford, California, CA 94305-
5332, USA.
pBabest2
hTERT
.. I
Figure 2.1 Schematic diagram of pBabest2 retroviral plasmid
pBabe Neo retroviral plasmid is the same structure as pBabest2 with the hTERT insert
missing.
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2.2 Cell Culture Techniques
All cell culture work was carried out using strict aseptic technique in Class II laminar flow
hoods (Medical Air Technology Ltd, Manchester, UK). Reteroviral work with human
muscle cultures was carried out in category II containment facilities.
2.2. 1 Human muscle biopsy explant cultures
Human muscle biopsies were obtained from a healthy 23 year old male (line 1) and 28 year
old female (line 2) from the vastus lateralis muscle of the thigh. The tissue was placed in a
vial of Dulbecco's modified Eagle's medium (DMEM) with 10% foetal bovine serum
(FBS), 20mM HEPES buffer, 2mM L-glutamine, SOU/ml penicillin and 20ng/ml
streptomycin for transportation. The muscle biopsies were cut into cubes of approximately
Smm by Smm. The muscle samples were spread out among petri dishes and covered in 2ml
PBS, or enough to just coat the plates and the samples. The plates were then put in a S%
CO2 humidified incubator for 2 hours. After this time the human muscle biopsies were
removed and the plate was covered in Sml of DMEM with 10% PBS 20mM HEPES
buffer, 2mM L-glutamine, SOU/ml penicillin and 20ng/ml streptomycin and left in the
incubator overnight. The next day the medium was replaced with 10ml fresh media.
2.2.2 Optimisation of growth conditions for human muscle cells
The initial culture conditions for the growth of human muscle cultures (HMC) were
established by Karen Steeghs as reported in Wootton et al 2003. Muscle cell cultures were
grown in 10% DMEM supplemented with 10% (v/v) FBS, 20mM HEPES buffer, 2mM L-
glutamine, SOU/ml penicillin and 2Ong/ml streptomycin. The optimal growth conditions for
the muscle cell cultures were determined by growing hTERT-infected and uninfected
HMCs in different media and serum concentrations for 20 days (see Table 1). The MPD of
the cells were recorded to determine the optimum medium conditions (See fig la). All
medium used had 20mM HEPES buffer, 2mM L-glutamine, SOU/ml penicillin and
2Ong/ml streptomycin added.
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Table 2.1 Comparison of different culture conditions for growth ofHMC
Media Serum
Dulbecco's modified Eagle's medium 10% FBS
20%FBS
Ham's FlO 10% FBS
20%FBS
Ham's Fl2 10% FBS
20%FBS
The MPD that cells achieved was recorded to determine the optimum medium conditions
for cell growth. The formula was according to Paul et al1975
MPD = (log Nb - log Na) X 3.32
where Na = initial cell number
Nb = final cell number
Itwas determined that 10% (v/v) foetal bovine serum in DMEM was optimum for growth
(see figure 3.4)
2.2.3 Passaging of human muscle cells
The HMCs were routinely cultured in DMEM supplemented with 10% (v/v) FBS, 20mM
HEPES buffer, 2mM L-glutamine, 50U/ml penicillin and 20ng/ml streptomycin at 37°C in
a 5% CO2 humidified incubator. Medium changes were carried out every 3-4 days and
cells were passaged when they reached 70-80% confluence. To passage the cells, medium
was removed and the cells rinsed with 1X PBS to remove any residual serum.
Trypsin/EDTA was added and the cells incubated for 3-5 mins or until the cells were
rounded up and became detached from the plate. 10% DMEM was added to inactivate the
trypsin, cells counted and pelleted by centrifugation at 1000rpm for 5 mins. The pellet was
resuspended in 10% DMEM and seeded at an appropriate density for experiments.
2.2.4 Cryopreservation and thawing of muscle cells
Stocks of cells were cryopreserved at different MPDs. Cell were maintained in culture and
when ready to be cryopreserved they were trypsinised, neutralised with medium and
pelleted. Cells were preserved at 106 cells in 1ml of freezing medium (10% (v/v) DMSO in
growth medium with 20% FBS) in cryotubes, 1ml per vial. The cryotubes were wrapped in
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cotton wool and placed in a -70°C freezer for 24 hrs to freeze slowly. The following day
the cells were stored in liquid nitrogen.
To thaw the cells the cryotubes were removed from liquid nitrogen and immersed in a
large volume of 37°C water. The cells were resuspended in l Oml of normal growth
medium (10% DMEM) and then pelleted by gentle centrifugation at 1000rpm for 5 mins,
to remove the DMSO. Finally the cells were resuspended in growth medium and plated.
2.2.4 Growth of cells in low oxygen
Cells were removed from normal culture conditions and placed in low oxygen conditions.
The cells used where split in the normal fashion and then placed in DMEM supplemented
with 10% (v/v) FBS, 20mM HEPES buffer, 2mM L-glutamine, SOU/ml penicillin and
20ng/ml streptomycin and media antioxidant N-(tert)-butyl hydroxylamine at a
concentration of lOOIlM. This removes the oxygen from the media. The cells were then
placed in an incubator at 37°C at 5% oxygen.
2.3 Mycoplasma testing of muscle cell lines
Antibiotic- free medium which had been in contact with the cells to be tested, for at least
48hrs, was removed. This medium was incubated with 104 normal rat kidney (NRK)
indicator cells. The NRK cells were incubated in at 3rC tissue culture incubator for 2-3
days. The medium was then removed and the cells were washed in PBS twice. The cells
were fixed in methanol/acetic acid (3:1), added slowly then poured off, and replaced with
another Sml of fixative. This step was repeated and finally the fixative was left on for
10mins. After the fixative was removed 0.05IA-g/mlHoechst 33258 in PBS was added and
left for 10 mins. Cells were then washed twice in distilled H20 and mounted in
Mcllvanies's buffer (O.2M Na2HP04, O.lM citric acid). Cells were examined using a
fluorescence microscope.
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2.4 Production of retroviruses
Phoenix A packaging cells were plated 2X106 cells in a 6cm plate. 24 hrs later Sug of
retroviral plasmid DNA was added to lOO!-l1of OPTI-MEM in one falcon tube (Bectin
Dickinson) while in another 2S!-l1of lipofectamine in 7Sul of OPTI-MEM was added. The
2 solutions were mixed and incubated at room temperature (RT) for 45 mins to form
complexes The cells had their medium removed and were washed twice with 1 X PBS.
0.8ml of OPTI-MEM was added to the complexes and the mixture added to the Phoenix A
cells. The cells were then incubated for Shrs in a CO2 incubator at 37°C. The transfection
mixture was removed and the cells were washed twice with growth medium (10% DMEM)
and incubated overnight in 10% DMEM. The medium was replaced 24 hrs later with 10%
FBS in DMEM. 24 hrs later the medium was removed and filtered through a 4.S!-l filter
(Gelman Science). The virus-containing medium was flash frozen on dry ice in 1ml
aliquots and stored at -70°C until required.
2.4. 1 Titration of Viruses
The day before titration, 1 X 105 NIH 3T3 fibroblasts were plated on 6 cm dishes. Next
day serial dilutions of the virus were mixed with 10% FBSIDMEM with 4!-lglml polybrene
(Sigman Aldrich, Poole, UK). Polybrene is a cationic reagent which aids in the 'sticking'
of the virus to the cell membrane and therefore improves infection efficiencies. 2ml of
each of the dilutions were placed on the NIH 3T3 cells and incubated in a CO2 incubator
for 3hrs. To minimise the toxic effects of the polybrene, it was diluted by adding 4ml of
growth medium to the dishes. All of the plates were re-fed the next day with growth
medium. 24 hrs later the appropriate concentration of antibiotic was added and the cells
selected for 2 weeks or until uninfected control NIH 3T3 plates were dead (see table 2).
The plates were fixed in 3% (v/v) paraformaldhyde/PBS and stained in 10% (v/v) giemsa
for 30 mins. The plates were washed in double distilled H20 and allowed to dry. The
number of colonies on each plate were counted and expressed as colony-forming units/ml
of supernatant. The muscle cells were infected at a 1:1 ratio of virus:cell where possible.
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2.4.2 Determination of antibiotic selection concentration
Kill curves for each of the different cell types/cultures were established to determine the
appropriate concentration of antibiotic to use during selection and generation of stable
pools and clones. Cells were plated at a density of 105 cells in 60mm plates and a range of
antibiotic concentrations which resulted in complete cell death after 2 weeks was taken as
the appropriate antibiotic concentration to use during selection. These concentrations are
listed in table 2.2
Cell line Antibiotic Concentration
NIH3T3 0418 ( Invitrogen, Paisley, 1 mg/ml
UK)
NIH3T3 Puromycin ( Sigam, Dorset) Iug/ml
Table 2.2 Concentration of antibiotic used in transfections
2.4.3 Retroviral infection of human muscle cells
The cells to be infected were seeded at a density of lOscell/6cm dish 72hrs prior to
infection. Polybrene (8mg/ml) was added to the viral supernatant which contained between
105 and 104 viral particles and the total volume made up to 5mls with 10% DMEM. The
cells and the viral supernatant were incubated at 37°C for 4 hrs and the medium replaced
with fresh 10% DMEM and the cells left overnight. Next day the cells were harvested and
plated at a density of 3 X 105/9cm dish, allowed to recover for a further 72 hrs and then
placed under appropriate selection until resistant colonies had appeared. Pools of resistant
colonies were frozen down or individual clones were picked and expanded prior to
cryopreservation in 1ml cryotubes (Nunc, Wiesbaden, Denmark). The ampoules were
stored in the liquid nitrogen tank until required.
2.5 Giemsa staining of cultured cells
Cells were washed twice in PBS and fixed in 10% (v/v) formaldehyde/PBS for 30 mins.
The cells were then washed in milli-Q H20 (Millipore Milli-Q Systems, UK) and stained
with 10% (v/v) giemsa/milli-Q H20 for 30 mins. After 2 further washes in milli-Q H20 the
plated were air-dried and observed under a low power (X 10 magnification) light
microscope (Zeiss) and colonies counted.
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2.6 Soft agar colony forming assay
Agar was prepared at 0.8%w/v and 1.6%w/v with Bactoagar (DIFCO, Detroit, MI) and
distilled water. This was autoc1aved and allowed to cool to 40°C. Double strength DMEM
was made up with 40% FBS. The 1.6%w/v agar was mixed with the 2X DMEM/40% FBS
in a ratio of 1:1 giving a final concentration of 0.8% agar. This was used to coat the bottom
of the plates (10mls per each 9cm plate), which were put in the incubator at 37°C and 5%
CO2 to set. The 0.8%w/v agar was mixed with the 2X DMEM/40% FBS in a ratio of 1:1
giving a final concentration of O.4%w/v agar. Cells were mixed with this top layer of agar
and poured onto the coated plates. The cells were plated at 1 X 104 for HeLa cells and 1 X
105 for HeLa cells, HFF cells, HMC T2 and HMC TIS. The plates were placed in and
incubator with 5% CO2 at 3~C. They were fed weekly with 0.8% agar mixed equally with
2X DMEM/40% FBS. The colonies were counted and photographed with a digital camera
after 5 weeks.
2.7 Low serum assay
Cells were plated at 5 X 104 in 3cm dishes in DMEM with 10% (v/v) FBS or 0.2% (v/v)
PBS. Each week the cells were trypsinised and passaged as indicated in section 2.3.3. The
cells were counted and their MPDs were recorded each week for 10 weeks.
2.8 Senescence associated {J-galactosidase(SABG) assay
Cells were maintained in culture until growth rates ceased as indicated by MPD or in the
case of hTER- infected cells at 44MPD. The cells were washed twice in PBS and fixed in
3% formaldehyde (v/v) in PBS for 5 mins at RT. Cells were then rinsed again in PBS and
stained for SABG as described by (7). Cells were incubated with 2ml of X-gal staining
solution (50mM MES, 150mM NaCI, 2mMMgC~, 5mM ~Fe (CN)6.H20 (potassium
ferrocyanide), 5mM K3Fe(CN6) (potassium ferricyanide) and Irng/ml X-gal) at pH 5.8 in a
6cm dish. The plates were incubated at 3~C in a humidity box for 16 hrs. The cells were
rinsed in milli-Ofl-O and visualised with a light microscope, scored for blue ~-
galactosidase positive cells and photographed.
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2.9 5-Bromo-2'-deoxy-uridine incorporation analysis
5-Bromo-2'-deoxy-uridine (BrdU) incorporation analysis was carried out using the BrdU
labelling and detection kit (Roche, Germany). Reagents were supplied as kit components.
Cells were plated in 8 chamber slides (Nalge Nunc, USA) at a density of 3 X 103 cells per
well. The cells were maintained in growth medium for 48 hrs. BrdU labelling reagent was
added to sterile medium at a concentration of 1Ol-tmolper ml. This was incubated on the
cells for 48 hrs at 3rC in a 5% CO2 incubator. The cells were then washed three times in
PBS and fixed in 70% (v/v) ethanol (in 50mM Glycine Buffer, pH 2.0) for 20 mins at -
20°C. The slides were washed again in PBS and incubated overnight at 4°C with anti-BrdU
mouse monoclonal antibody diluted (1:10) in incubation buffer (66mM Tris-buffer,
0.66mM MgCl2 and 1mM 2-mercaptoethanol). Following a further 2 washes in PBS wash
buffer, the cells were incubated with an FITC-conjugated anti-mouse IgG antibody (diluted
1:10 with PBS) for 10 mins at RT in the dark, in a humidifier box. The cells were washed
again with PBS wash buffer and air-dried. The gasket was removed and the slides were
mounted in VecashieldlDAPI (Vector Laboratories, Peterborough, UK). Slides were sealed
using clear nail polish and cover slips, then stored at 4°C until ready to view. Visualisation
of slides was carried out using a Zeiss Axioskop fluorescent microscope. Images were
captured using a CCD Camera System (Princeton Instruments).
2.10 Immunohistochemistry
2.10. 1 Preparation of frozen sections
Sum frozen sections of muscle from implanted mice, untreated RAG-1 mice and from a
normal human donor were cut on the cryostat.
2.10.2 Preparation of paraffin tissue sections
Muscle biopsies were fixed in formalin (1O%(v/v) formaldehyde in PBS pH 7.6) for 24 hrs
before embedding in paraffin using standard procedures. 6l-tm sections were cut using a
Leica microtome. The sections were floated in a 50°C water bath and collected on glass
slides. The sections were dewaxed and rehydrated in coplin jars using standard procedures.
Briefly, sections were dewaxed in two changes of Histoclear and rehydrated through
graded alcohols, 100%, 70%, 50% ethanol/milli-Q H20 (v/v)
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2.10.3 Histological Staining ofMuscle Sections
Mayer's haematoxylin-eosin staining of muscle tissue was routinely performed to examine
the morphology of the muscle tissue. The sections were placed in haematoxylin solution
for 5mins and washed for 3mins. The sections were counterstained with eosin for 30-
60secs, rinsed in running tap water for 30 secs, then dehydrated through graded alcohols
and cleared in Histoclear and placed in mounting medium.
2.10.4 Desmin staining ofmuscle cells
Cells were grown on chamber slides at a density of 1 X 103 and washed 3 times in PBS.
The slides were then fixed in acetone at 4°C for 20 mins and allowed to air dry. The
sections were blocked with 2 % horse serum (Autegen Bioclear, UK) in PBS for 30 mins.
The slides were incubated for 60 mins at RT with a mouse monoclonal antibody directed
against desmin (clone D33, at a dilution of 1:100, Dako, USA). After washing with PBS
the cells were incubated with secondary and tertiary antibodies from the avidin biotin
complex (Vectastain Peroxidase Mouse IgG ABC kit, Vector Laboratories Inc,USA) as
per the manufacturer's instructions and counterstained with 3, 3'diaminobenzidine (DAB,
Vector Laboratories, UK).
2.10.5 Spectrin staining ofmuscle tissue
8IAmfrozen sections of muscle from the implanted mice, untreated RAG-l mice and from a
normal human donor were blocked with 2 % (v/v) horse serum in PBS for 30mins. All
tissues were incubated with the primary antibody spectrin ( NCL - SPEC2, at a dilution of
1:100, Novocastra Labs, UK) overnight at 4°C. The slides were washed and stained using
the Vector MOM Immunodetection Kit following the manufacturer's instructions (Vector
Laboratories Inc,UK). Tissue was visualised using DAB. The tissue was examined using a
light microscope and digitally photographed.
2.10.6 p16 staining ofmuscle cells
Cells were grown on chamber slides at a density of 1 X 103 and washed 3 times in PBS.
The slides were then fixed in acetone at 4°C for 20 mins and allowed to air dry. The
sections were blocked with 2 % horse serum (Autogen Bioclear, UK) in PBS for 30 mins.
The slides were incubated for 60 mins at RT with a mouse monoclonal antibody directed
against p16 (clone 50.1, at a dilution of 1:50, SantaCruz). After washing with PBS the cells
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were incubated with secondary and tertiary antibodies from the avidin biotin complex
(Vectastain Peroxidase Mouse IgG ABC kit, Vector Laboratories Inc,USA) as per the
manufacturer's instructions and counterstained with 3, 3'diaminobenzidine (DAB, Vector
Laboratories, UK).
2. 11 Microbiological Techniques
2.11.1 Transformation of bacteria with plasmid DNA
E coli DHSa competent cells were thawed on ice and 20~1 transferred into a prechilled
1.5ml microcentrifuge tube. Plasmid DNA diluted to a final concentration of 10ngl~l-
20ngl~1 was added to the DH5a cells, mixed and incubated on ice for 30 mins. The cells
were then heat-shocked for 40 s in a 42°C water bath and then placed on ice for 2 min.
80~ of S.O.C. Medium (GibcoBRL, Paisley, UK) was added and the mixture agitated in a
shaker at 225rpm for 1hr at 3-r>C to allow the induction of the antibiotic resistance gene
ampicillin. The cells were then spread on LB* medium plates contining 1.5% (w/v) agar
supplemented antibiotic. Plates were incubated in an inverted position at 3-r>C and clonies
were transferred into LB medium the next day.
* LB Medium is also known as Luria-Bertani which consists of 109 bacto-tryptone (Difco,
Surrey, UK), 5g bacto-yeast extract (Difco, Surrey, UK), 109 NaCl in lltr of deionised
H20 at pH 7.0. LB Medium is prepared in-house at the BICR.
2.12 DNA extraction and analysis
2.12.1 Preparation of plasmid DNA
Plasmid DNA was extracted using the QIAGEN Midi Kit(alkali method described by
(126). 500ml of LB medium containing 100~g/ml ampicillin ( Sigma, Poole, UK) in 15mls
sterilin tubes were inoculated with a single bacterial colony from the agar plate (previously
transformed, see above section 2.12). The cultures were then placed into a 3-r>C shaker for
16 hrs. The bacterial cells were then harvested from the broth by centrifugation at 6000 X
g for 15 mins. The supernatant was removed and the pellets were resuspended in 10ml of
buffer P1 (50mM Glucose 25mM Tris-HCI pH8, 10mM EDTA pH8). An equal vol of
buffer P2 (0.2M NaOH/1 %(w/v) SDS) was added to lyse the cells and denature the DNA.
The tubes were gently mixed by inversion and then incubated for 5mins at room
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temperature. 10ml of cold buffer P3 (potassium acetate/glacial acetic acid, 3M and 2M
respectively) was then added and then incubated on ice for 20 mins. The tubes were
centrifugated at 20,000 X g for 30 min at 4°C to separate the plasmid DNA from the cell
debris. The supernatant was removed and the pellet was re-spun at 20,000 X g for 15 mins
at 4°C. lOml of buffer OBT was added to the OIAGEN-tip 500 and allowed to empty by
gravity. On completion of the spin the supernatant was removed and added to the
QIAGEN-tip and allowed to enter the column by gravity. The column was then washed
twice with 30ml of buffer OC and the DNA was eluted from the column by the addition of
15ml of buffer OF. The DNA was collected in a 30ml glass tube and precipitated by the
adding of 0.7 volumes of isopropanol. The mixture was centrifuged at 15,000 X g for
lOmins at 4°C and the supernatant removed. This left a DNA pellet which was washed
with 5ml of 70% (v/v) ethanol and then centrifuged again for 10 mins at 15,000 X g, 4°C.
The supernatant was removed and the pellet was then dissolved in TE buffer (Tris/EDTA),
pH 8.0 and plasmid concentration was determined (see section 2.13.4)
2.12.2 Preparation of genomic DNA from tissue culture cells
1X106 cells were harvested and pelleted by centrifugation (see section 2.2.3). The cell
pellets were resuspended in 1ml of 1 X PBS and transferred to 1ml eppendorf tubes and
spun at 13,OOOgin a microcentrifuge for 10 mins at 4°C to re-pellet the cells. The PBS was
removed, the cell pellets resuspended in 0.5ml of digestion buffer (lOmM TRIS-HCI
pH7.9, 1mM EDTA, O.3M sodium acetate, 1% 9w/v) SDS and 200~glml proteinase K)
and digested overnight at 37°C in a shaking incubator. The following day undigested cell
debris was pelleted by centrifugation at 13,OOOgfor 10 mins at 4°C. The supernatant was
removed and 1ml of 100% ethanol added, inverted several times until threads of DNA
were visible. The DNA was either spooled out using a glass pasteur pipette or pelleted by
centrifugation at the same speed and temperature as above for 15 mins. The DNA was then
washed with 70% (v/v) ethanol and allowed to air dry for 10 mins. The DNA was
resuspended in 500~ of TE buffer, incubated at 65°C for 10 mins and the tubes flicked to
disperse it. The DNA was then stored at -20°C and used for PCR and southern blotting.
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2. 12.3 Synthesis of Oligonucleotides
Oligonucleotides were synthesised at the BICR as a core service on a 394 RNNONA
synthesizer (Applied Biosystems,UK) using Cruachem reagents. Oligonucleotides were
deprotected and lyophilised using Hybaid Proligo system and supplied in this form. The
oligonucleotide was resuspended in 500f.l1 of milli-Q H20 and the concentration
determined as described below (section 2.13.4).
2. 12.4 Quantitation of DNA Concentration
DNA was quantified by spectrophotomeric determination of its UV light absorbency. 5f.l1
of sample was added to 495f.l1of de-ionised water and the absorbency of the solution was
measured at 260 nm and 280 nm in a quartz cuvette, using de-ionised water as a blank. The
concentration of the solution was calculated using Beer's law which states that an optical
density of 1.0 at 260 nm corresponds to a concentration of 50mglml for double-stranded
DNA and 30mglml for single-stranded oligonucleotides. Pure preparations of DNA have
an absorbance ratio between 1.5 and 1.9 at A260/A280.
2.13 Electrophoretic Techniques
2. 13. 1Agarose gel electrophoresis of non radioactive PCR
products
Non-radioactive peR products were separated on the agarose gels and visualized by
staining with ethidium bromide and UV transillumination. Gels were prepared by melting
the appropriate amount of agarose in 1 X TAE (40 mM tris-acetate and 2mM EDTA pH8)
by microwaving on a medium heat for 2-3 min. A final concentration of 0.5JA.g/mlof
ethidium bromide (Sigma,Poole, UK) was added to the agarose and the gel was poured into
the appropriate casting tray. The gel was then allowed to set and once solid, placed in the
electrophoresis tank containing 1 X TAE running buffer. 1/5 vol of loading buffer (50%
glycerol, 100mM EDTA, 1 X TAE, 0.1% bromophenol blue) was added to each sample.
The samples were loaded into the appropriate wells and electrophoresis performed for 1hr
at 100V to ensure separation of bands. Samples were run against an appropriate mass
ladder to estimate the size of the fragments.
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2.13.2 Denaturing Polyacrylamide Gel Electrophoresis
The radio-labelled PCR products of polymorphic markers (see section 2.15 below) were
resolved on a range of different percentage polyacrylamide gels under denaturing
conditions. This range was dependent on the length of the PCR product (See table 3). A gel
solution was prepared from the Flowgel (Flowgen Instruments, Staffordshire, UK) stock
solutions using 75M Urea (Flowgel Diluent), 2S% w/v acrylamnide solution 19:1
acryl:bisarcryl and 75M urea (Flowgel Concentrate), and Flowgel Sequencing Buffer
comprising 7.SM urea, 1M tris-borate and 20mM EDTA pH8.3. The solution was
polymerised by the addition of 6S0~1of 10% w/v ammonium persulphate and 100~1of
TEMED per 100ml of gel solution. This solution was then poured between glass plates
separated by OAmm spacers and allowed to set at RT for approximately 1 hr. Before
loading the gels were pre-run at 60W for 45 mins in 1 X TBE (90mM tris-borate and 2mM
EDTA pH 8.0) to warm the gels. Denaturing gel-loading buffer (98% vlv formamide,
lOmM EDTA pH 8.0, 0.1% w/v xylene cyanol and 0.1% w/v bromophenol blue) was
added to the completed PCR reactions (5ul added to 10ul reaction) and this mixture
denatured by heating at 95°C for 5 mins and immediately quenched on ice. 20J..t1of this
mixture was subjected to electrophoresis at SOWfor approximately 4 hrs depending upon
the size of the PCR product. The gel was then transferred to a sheet of whatman 3M paper
and dried under vacuum at 80°C for 45 mins. The PCR products were detected by
autoradiography using Kodak X-omat film (Kodak, UK).
2.14 peR and analysis of amplification products
2.14. 1 Aficrosatellite Analysis
Total reaction volumes were 10~1 containing 4at,g genomic DNA, lOmM tris-HCI, pH
8.3, 50mM KCI, 1.5mM MgCI2, 10% (v/v) dimethylsulphoxide, 1f.tM of each
oligonucleotide primer, 200~M of each deoxynucleotide triphosphate, OAf.t1 of
[a32P]dCTP (24.7kBq/f.t1Amersham, UK) and 0.5 units of Taq polymerase (PE Allied
Biosystems, UK). Reactions were subjected to an initial denaturation step of 5 min at 94°C,
followed by 30 cycles of 30 sec at 94°C; 30 sec at 5S-6SoC;and 30 sec at 72°C, and a final
extension step of 7 min at 72°C. Radiolabelled samples were electrophoresed on 4-10%
polyacrylamide gels under denaturing conditions. Gels were dried then exposed to X-ray
film to visualise the resolved reaction products. The following primers were used to
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examine specific cell cycle regulators: D17S1353B (p53), D13S153 (pRB), DllS922
(P57), D6S1051(p21) and D9S1870 (INK4A)(see table 2.3)
Table 2.3 Summary of Different percentages of polyacrylamide gels used to separate
microsatellite products
Microsatelite marker % of polyacrylamide in gel Size of product
D9S1870 INK4A 6% 179 - 221b_Q
DllS922 p57 8% 88 -138bp
D6S1051 p21 5% 223 - 239bp
D13S153 pRB 7% 155b_Q
D175S1353 p53 6% 184 -122bp
2. 15 Protein analysis
2. 15. 1 Western blotting and antibodies
This was performed essentially as described by Munro et al (127, 128). 100 ug of protein
was subjected to electrophoresis on 10% (c-myc) or 17% (CDKIs) non-denaturing
polyacrylamide gels. Primary antibodies were: p16INK4A (C-20; Santa Cruz Biotechnology,
California, U.S.A.), ERK2 (Transduction Laboratories) and c-myc (N-262; Santa Cruz
Biotechnology). The SV40-immortalised human keratinocytes line SV6-1 HFK was used
as a positive control for p16INK4A and the human squamous cell carcinoma line BICR31 as
a negative control. BICR31 harbours a homozygous deletion of the INK4A locus. The
HaCaT line is an immortal human skin keratinocyte line that expresses high levels of
p15INK4B. The human squamous cell carcinoma line BICR78, which does not express
p15INK4B mRNA, served as a negative control for p15INK4B• HFF UV are human foetal skin
fibroblasts irradiated with 8 milli-joules of ultraviolet light from a stratalinker 2400
(Stratagene, USA) and harvested 16h later.
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2.15.2 Te/omerase Activity
Cellular extracts were prepared and assayed for telomerase activity using the TRAPeze kit
(Intergen, Company, UK) following the manufacturer's instructions. The PCR products
were resolved on 10% (v/v) non-denaturing polyacrylamide gel. To semi-quantitate
telomerase activity, the exposure of the 36bp internal standard to the telomerase ladder was
compared. The intensity of the bands were measured using the Bio-Rad molecular imager
and quantified by Quant One imaging software.
2.16 Regeneration of striated muscle in vivo
The main part of this experiment was carried out by Dr D Watt at Imperial College. I
provided the cells for injection, cut the sections, stained, examined and photographed them.
Dr Watt provided the RAG-1 mice, injected the hTERT-transfected and control cells,
sacrificed the animals and dissected the area affected.
RAG-l mice were selected because they would not reject the implanted human muscle cell
and could with stand the procedure. The RAG-1 mice were irradiated with a single dose of
X-radiation, to inhibit regeneration of the mouse own cells, before the procedure. The
grafted cells are then more likely to regenerate damaged muscle (Watt et al 1982). Barium
chloride, a myotoxic agent, was administered by injection. Barium chloride was used as it
stimulates necrosis of the muscle without damaging the basement membrane (Caldwell et
al1990). Forty eight hrs after injection, the right tibialis anterior (TA) was implanted with
cells. The cells were first trypinsied and counted. 3x1OScells were pelleted by centrifuge.
The skin over the tibialis anterior muscle was surgical excised and the pellet of cells was
delivered. The cells were placed using a glass PCR pipette and injected through the
epimysium into the muscle. The tip of the pipette was stained with red dye to allow
identification of the injection site latter (Gibson et aI1995). Six TA muscles received T 15
cells, two, T2 cells and three, control human muscle cells. 25 days after implantation, the
recipients were sacrificed and frozen sections prepared. These were stained with H+E or,
for spectrin by immunochemical methods. The number of spectrin-positive fibres,
indicative of myofibre fusion, was observed by counting at least 5 fields adjacent to the
injection site. Only fibres positive for spectrin on all sides were considered positive. At
least 1000 cells were scored per sample.
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3 Results
3.1 Extension of replicative lifespan of HMCs by hTERT
expression
HMCs was explanted from a needle biopsy specimen, from healthy volunteers. Ethical
permission was obtained from the North Glasgow Hospital University Trust. Cells were
allowed to grow out of the biopsy and transferred into petri dishes. After 25 mean
population doublings (MPD) the HMCs were infected with either a retrovirus containing
hTERT or with a neomycin (NEO) selection marker alone. Previously a line of human
muscle cells had been infected in the same manner from a different donor after 5 MDPs by
Dr K Steeghs who carried out preliminary work before the start of my PhD. Mass culture
and selected culture were grown under G418 selection. From the first line, five hTERT
expressing clones (Tl, T2, T3, T4 and Tl5) and 3 empty vector controls expressing the
neomycin resistance gene (NEO 1, NEO 2 and NEO 3 ) were studied and the mean
population doublings (MPD) was determined.
Before and after transfection with the hTERT the muscles cells retained the same
appearance. The cells were mono-nucleated and grew in a single layer. When plated at low
density the muscle cells had a large oval shape; however as the cells approached
confluence they became more spindle shaped. The cells always remained mono-nucleated
even at this point. The cells were never allowed to reach full confluence. When a plate
was 70-80% confluent the cultures were split. In the case of TlS, the plate occasionally
required splitting twice a week. Each time the cultures were split the cells MPD was
calculated and recorded. The growth rates of the clones can be seen in Figure la. As seen
from the graph the NEO clones all senesced at approximately 37 MPDs. All of the hTERT
expressing cells had bypassed senescence although there were variations in cell
proliferation rate. Clone T1 showed an initial slow growth rate but it did not reach
senescence. In fact over time the growth rate of T1 increased. This alteration in growth
rate suggests that a secondary event had taken place which allowed it to overcome
senescence. TI, T3 and T4 all showed a consistent linear growth rate, which did not
change considerably over the course of time. The most striking result was seen in TlS. It
displayed a consistently fast growth rate and has bypassed 120 MPDs. All of the hTERT
expressing clones display extension of proliferative lifespan of at least 60 MPDs.
Figure 3.1 Growth curve of hTERT clones and NEO clones
Telomerase expressing HMCs clones show variable growth rate. Each clone is indicated
on the graph. In the first set of transfections (A) all of the Neo-infected clones senesced
after 21-28 MPDs, whereas the hTERT-infected clones have completed between 45 (T1)
and 125 (TIS) MPDs. In the second transfection (B) the neo pool (HMCN) senesced at 36
MPDs while and the neo clone (NA), senesced at 40 MPDs. The hTERT transfected pool
(HMCT) continued to proliferate and at last calculation had reached 57 MPDs and the
hTERT clone (TC) had by passed 48 MPDs.
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Figure 3.1A The growth curve of the first infected cell strain
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Figure 3.1B Growth curve of the second infected cell strain
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To determine that the cells were in a cycling state, the levels at which they incorporated
bromodeoxyuridine (BrdU) was measured. This can be seen in Figure 3.2. Using HeLa
cells as a control it was seen that the incorporation of BrdU was low in Neo 3 after 21-28
MPDs, with considerable higher incorporations in all of the hTERT expressing clones.
The level of BrDU incorporation was directly comparable to the clones growth rate. With
T15 showing incorporation at the same level as the HeLa control cells.
Transfected cells were tested for the expression of ~-galactosidase, which is a marker for
senescence. The results for this experiment can be seen in Figure 3.3. HMC Neo cells
stained positive while HMC hTERT cells remained negative. On observation of the cells,
all of those which had been infected with hTERT had a spindle shaped appearance which
is characteristic of proliferating cells. While those which were transfected with NED or
control HMCs as time passed, showed the characteristic flattening and widened shape of
senescent cells.
Figure 3.2 BrdU incorporation in cycling cells
The incorporation of bromodeoxyuridine (BrdU) into the different HMC clones and
cultures demonstrates the difference in the growth rates. With TI5 the fastest growing
line, showing the highest level of incorporation and Tl, the slowest growing line,
demonstrating the lowest level of incorporation.
BrdU incorporation was analysed at 25 weeks after initial transfection. The experiment
was performed 4 times with approximately 5 % variation between experiments.
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Figure 3.2 BrdU incorporation in cycling cells
Figure 3.3 p-galactosidase incorporation in transfected and non transfected
cells
Staining of the Neo-control HMC line 2 after 37 MPDs for senescence-associated p-
galactosidase shows numerous flat cells that stain positively and appear blue on the
photograph (A) In contrast the hTERT infected HMC cells showed few positive cells (B).
Arrows denote positive staining.
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Figure 3.3 ~·galactosidaseincorporation in transfected and non transfected
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3. 1. 1 Discussion
Itwould have been expected that the rate of growth would remain constant and this was the
case for T2, T3 and T4, however, this was not true of all the clones. The most interesting
aspect of the cell growth rates was the difference between the different TERT clones. In
most studies showing immortalisation, this difference in growth rate has not been
discussed because full populations of cells are examined and not clones derived from an
individual cell (129). When examining Werner syndrome fibroblast (a disorder
characterised with early ageing) it was discovered that these cells had limited replicative
potential, thought to be due to chromosome instability. To assess the role of telomere
length in the senescence of these cell single telomeres of individual clones were examined,
rather than examining a pool of cells. There were great differences between the rates of
erosion of telomeres from clone to clone (between normal ranges and four times normal
range). Itwas suggested that in the pools of fibroblasts, cells with faster eroding telomeres
were being overpopulated by the still replicated 'normal' cells. Therefore the results were
not giving a clear picture. In the hTERT cells, if pools of cells were examined rather than
clones, it is easy to assume that TIS may have taken over the population and altered the
results.
The change in some of the growth rates may be due to a secondary alteration. This seemed
the most plausible reason behind the growth of Tl which suddenly accelerated after 20
MPDs. This cell line appeared to be approaching senescence but escaped and continued to
proliferate for another 30 MPDs.
TIS was the most interesting clone due to its high proliferation rate. This was much faster
than the other clones, reaching 120 MPDs. In fact, TIS has not stopped proliferating to
date. The success of this clone is unknown but it could be due to the fact that the cell was
immortalised at a primitive stage in the myogenic lineage. This would mean that the cell
would already have long telomeres and therefore be able to maintain these with the help of
hTERT. Also using retroviral vectors means that you cannot be sure where the gene has
inserted, i.e. it may have inserted into multiple sites. This may result in the expression of
other genes due to insertion mutagenesis. This may be giving TIS an advantage over the
other clones. Another possibility is that TIS is expressing more telomerase than the other
clones, and this could occur if the retroviral vector had entered at a site near to a strong
promoter which is highly transcribed.
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3.2 Growth conditions for transfected eel/lines
The cells lines were established in DMEM with 10% foetal calf serum, with added
penicillin and streptomycin. When examining the literature for the culture of human
muscle cells it was discovered that FlO was commonly used as the chosen medium.
Previous attempts at immortalisation with the same retroviral vectors, in Ham's FlO had
proven unsuccessful. Therefore, to test the importance of medium in these experiments
normal HMC cells was transferred into Ham's FlO after 25 MPDs, T2 was transferred after
70 MPDs and HMC T15 after 115 MPDs. The cells were grown for more than 100 days
and their MPDs were calculated, as seen in figure 3.4. All the cell lines grew more quickly
in DMEM compared to FlO. HMC cells grew for 4 more MPDs in FlO but grew for
greater than 10 MPDs in DMEM. TIS and T2 both entered senescence after being grown
in FlO. This experiment was repeated using 15% and 20% foetal bovine serum (FBS)
instead of 10% foetal bovine serum. In the case of HMC this increased the MPD by 2.5 for
20% FBS but this did not alter the result from the TERT clones. Both of the TERT clones
examined underwent senescence after 6 MPDs in the case of T2, and 1 MPD in TIS. This
result was not altered when the concentration of serum was increased to 20%. Therefore
for the rest of the experiments cells were grown in DMEM as described.
To further establish the importance of growth conditions, cells were also grown in low
concentrations of oxygen to see if this favoured the growth rate of the cells. Preliminary
results are shown (see table 3.1), and it appears to have no effect on cell growth rates.
Cell Line MPDs in normal oxygen MPDs in low oxygen
conditions over 3 weeks conditions over 3 weeks
HMC 4.5 4.2
TIS 7.8 8.2
Table 3.1 Effects of low oxygen on growth rates of HMC and T15 cells.
Figure 3.4 Growth rate of cells in different medium
A) HMCs show a reduced replicative lifespan in Ham's FlO medium compared with
OMEM. HMC line 2 (a) was cultured in OMEM with 10% foetal bovine serum and after
25 MPOs was either kept in DMEM (pink squares) or transferred into Ham's FlO (blue
diamonds). Clone T2(b) was compared in the two media as in (a) but it was transferred at
70 MPOs and clone TIS (c) was transferred into FlO at lIS MPDs.
B) Comparison of TIS and HMC in different culture conditions and their MPDs resulting
from these changes.
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3.2. 1 Discussion
There have been previous attempts to immortalise HMCs with hTERT, which were
unsuccessful (130). Why our protocol was successful and others have failed, is not
completely clear. However, what was evident is how the use of different media made a
difference in the ability of these cells to grow. It was merely by serendipity that the HMCs
were grown in DMEM since, this was the standard medium used in our laboratory for
growing fibroblasts. Itwas not until I searched the literature, that I was aware that Fl 0 and
Fl2 are the media more commonly used. It was at this point that I decided to see if
different media would alter the growth rates. I initially anticipated that the use of Fl 0 or
F12 would allow some of the slower growing clones to grow faster, but the opposite was
true. The use of FlO results in senescence of the hTERT clones. Therefore it is reasonable
to suggest that the choice of medium used may have led partly to the failure of other
groups to immortalise these cells. There are many differences in the formulations of
Ham's FlO and DMEM including the inclusion of biotin, Thiamine, and vitamin B12 in
Ham's FlO and six fold higher concentration of calcium in DMEM. It is likely however
that not only the medium but also the incubators, the reagents and other in-house factors
may playa role.
Another explanation for the success of this experiment was the early removal of the
selecting agent G4l8. G4l8 was removed as soon as the mock infected cultures died. It
has been shown that in normal human keratinocytes, if G4l8 is kept on the cells the
replicative lifespan of the cells decreases (131). Therefore this may have played a role in
the viability of the cells.
It was recently suggested that low oxygen concentrations may allow cells to grow for
longer (132, 133). To test this, a pilot experiment was set up. This initial experiment did
not seem to have any effect on the growth rate, however, and was hard to maintain as the
cells were susceptible to fungal infections. However I would not rule this out as I feel that
I may have not perfected the technique and would have liked to repeat this experiment on a
bigger scale and include cell line controls that are known to grow better in low oxygen.
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3.3 hTERT-expressing muscle cells lack transformed
properties
It has previously been reported that fibroblasts can have extended replicative lifespan by
transfection with hTERT without the malignant transformation (134). However since there
is such a strong relationship between telomerase activity and malignancy, the transfected
cell lines were tested for transformation.
3.3.1 Effect of low serum on MPD
Cells were grown in 0.2% FBS in DMEM over 10 weeks. Every 2 weeks cells were split
and MPD recorded. Figure 3.5 shows the total MPD over the 10 weeks using normal
HMC and HeLa cells as a control. As can be seen HMC control cells grew for 3 MPDS
while all hTERT infected cell lines could only manage less than 2 MPDs in 10 weeks. In
contrast T15, the fastest growing cell line, proliferates for 18 MPDs in the 10 weeks in
10% serum.
Figure 3.5 Observation of the growth in low serum
Proliferation ofHMC TERT clones in 0.2% FBS in DMEM is minimal over 10 weeks, and
is less than early passage HMC. HeLa cells were able to undergo considerable proliferation
under the same culture conditions. HeLa cells were used as a positive control and normal
HMCs at early passage used as a negative control. For comparison of the ability of cells to
grow in 0.2% FBS, TIS in 10% FBS in DMEM is shown. These results are from one
experiment with four replicates.
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Figure 3.5 Observation of the growth in low serum
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3.3.2 Cell growth in agar
The cell lines were then grown in agar to test for anchorage dependency. Human foetal
fibroblasts (HFF) and HeLa cells were used as negative and positive controls respectfully.
The HeLa cells grew in numerous colonies (as can be seen in Figure 3.6), however the
transfected cells failed to grow in agar. Colony efficiency of the HeLa cells was
determined (see Figure 3.7).
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Figure 3.6 Results of Agar assay.
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Cells were grown on plates coated with agar, After 4 weeks the visible colonies were
counted.
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Figure 3.7 Graph summarising the cloning efficiency in soft agar
Count of all visible colonies was performed and the cloning efficiency determined
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3.3. 1 Discussion
It was very important to examine the cells for signs of malignant transformation. None
was found as identified by lack of growth in agar and low concentrations of serum. This is
in keeping with reports of other cell types transfected with hTERT, induding fibroblasts
and retinal epithelium. Immortalisation of cells is not a straight forward exercise. Different
cell types require different techniques. For example, some cell lines are actually developed
from malignant cells, ego HeLa cells and rhabdomyosarcoma cells. Some normal cells
have been transfected with an oncogene, e.g. myocardial fibroblasts, mammary epithelial
cells and keratinocytes with HPV and lymphocytes, with EBV. In contrast, there are those
cells which are transfected with hTERT Le. fibroblasts and endothelial cells. These cells
are immortalised with hTERT alone. They tend to have fewer abnormalities than those
immortalised by other means. Therefore it was not surprising but promising that no sign of
malignancy was found in the hTERT-transfected HMCs. Even when the fastest growing
clone was selected, no signs of malignancy were found. My results are in keeping with
those of other workers.
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3.4 Determination of Cell Type
The TERT transfected cells lines were grown on glass chamber slides, fixed and stained
for Desmin. Desmin was used as it is one of the first proteins expressed when muscle cells
enter the myogenic lineage (see figure 1.13). All cells were desmin positive with
characteristic cytoplasmic staining (figure 3.8). Normal human muscle cells were used as
a positive control and human foetal fibroblasts (HFF) as negative control.
3.4. 1 Karotyping of Cell Lines
The chromosomes of all the cells lines were stained by Hazel Ireland and then I counted to
determine if there were any chromosomal abnormalities. Over 50 chromosomes spreads
where counted for four of the cell lines at 50 - 70 MPD and the number of chromosomes in
each spread noted. Figure 3.9 shows the hTERT expressing HMC cells had a modal
chromosome number of 46 and figure 3.10 a typical normal karyotype from T15.
Figure 3.8 Desmin staining
Positive desmin staining on control ofnonnal HMC CA), positive staining on clone TI5
cells (8) and a negative control ofHFF (C). The arrows show the positive staining cells.
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Figure 3.9 Showing the normal model number of chromosomes
Each graph denotes a clone of hTERT transfected HMCs: A - T1, 8- T2, C - T3,
O-T4 and E-T15. As can be seen from the graphs all have a modal chromosome
number of 46. These results are from one experiment.
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Figure 3.9 Showing the normal modal number of chromosomes for each of
the clones studied (A-B).
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Figure 3.9 Showing the normal modal number of chromosomes for each of
the clones studied (C-D).
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Figure 3.9 Showing the normal modal number of chromosomes for each of
the clones studied (E).
Figure 3.10 Typical karyotype for T15
The G-banded karyotype of HMCT 15 was typical of eight metaphases examined in detail
and revealed no obvious abnormalities. The analysis of the G-banding was carried out by
Hazel Ireland.
Figure 3.10 Typical karyotype for T15
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3.4.2 Discussion
Desmin was used as the muscle specific marker to determine if the cells were of the
myogenic lineage. The reason for this is that it is expressed early on in the differentiation
of cells committed to this lineage. It was expected that the cells from the healthy adult
volunteer would be at this stage in vitro. Desmin is also useful because it is expressed in
myogenic cells throughout their lifespan, unlike other markers e.g. myogenin and myf-S.
It is not only expressed in myocytes but also myotubes. As myocytes differentiate, they
join to become multinucleated and form myotubes.
By analysis of the model chromosome number and by specific examination of the cell
karyotype, no abnormalities could be seen. All chromosomes were present and there was
no genetic abnormalities were evident.
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3.5 Expression of telomerase and telomere length
To assess how the introduction of telomerase had affected the telomeres, telomere length
was calculated and telorne rase expression was measured. The initial experiment was
carried out by Dr Katrina Gordon and repeated by me. It was important to assess if the
introduction of telomerase could increase telomere length, and also if the transfection had
resulted in successful expression of telomerase. As can be seen from Figure 3.11 all of the
HMCs infected with hTERT are expressing telomerase. The cells which were infected with
the Neo control vector had no telomerase activity as indicated by the lack of TRAP ladder.
On examination of the telomere lengths it could be seen that the extension in telomere
length did not collate to the growth rate. TIS had telomere lengths which were similar to
that of T4, but T4 grew much slower than TIS. Also surprisingly T3, which had undergone
88 MPDs, had telomeres shorter than senescent HMCs.
Figure 3.11 TRAP assay and TRF blot for hTERT clones
A: Shows the TRAP assay performed on HMC Neo and HMC hTERT pools and clones.
CHAPS is a buffer alone control and TSR8 is a positive control supplied by the
manufactures of the assay. HI is the heat-treated control for each sample. 36bp band at the
bottom of the gel is an internal positive control to assess if the PCR has worked.
B: TRF Southern blot showing the average telomere length. The follow cell lines were
used as controls for TRF lengths: GM847 cells, long TRF lengths (TRF>10Kb), HeLa
intermediate TRF length (4-6Kb) and A 1898 short TRF length (4-6Kb) and A 1898 short
TRF length (2-3Kb).
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Figure 3.11 TRAP assay and TRF blot for hTERT clones
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3.5. 1Discussion
The results from the TRF blot show progressive shortening of the telomcres as the Neo
pool they approach senescence, while the serial cultivation of the hTERT pools show a
slight increase in telomere length. However there does not seem to be direct relationship
between telomere length and growth rate. Also T15 does not appear to express higher
amounts of telomerase than the other clone. The telomere length for T3 suggests that this
clone has the ability to replicate with short telomeres and recruit telomerase.
3.5.2 The changes in growth rate for T1
As can be seen from Figure 3.1 the growth rate of Tl has changed considerably over time.
At 30 weeks it was thought that the cell would senescence at 30 MPDs, however at this
point the growth rate changed and the clone has continued to proliferate. It is likely to
assume that this clone has undergone a secondary alteration. To try and address this TRAP
assays were performed on Tl at 20 MPDs and Tl at 44 MPDs, to find out if after this
change the cell was now expressing more telomerase. Using T2 as a control, the
concentration of protein to be used was assessed by assaying serial dilutions of the protein
extracts. If too much protein is used the peR reaction becomes saturated thus making any
quantification of TRAP products invalid. The titration TRAP assay can be seen in Figure
3.l2A and the TRAP assay for early and late Tl in figure 3.l2B
Figure 3.12 TRAP assay to asses for changes in T1 telomerase expression
A: Titration ofT2 Protein Extract to assess appropriate concentration of protein to be uses.
B: Trap for early passaged TI cells and late passaged Tl cells. T2 and TIS were used as
positive controls. In both cases CHAPS is a buffer alone control and TSR8 is a positive
control supplied by the manufactures of the assay. HI is the heat-treated control for each
sample. Band of positively at the bottom of the gel is an internal positive control to assess
if the PCR has worked.
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Figure 3.12 TRAP assay to determine telomerase activity in T1 cell line.
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3.5.2.1 Discussion
The concentration of protein to use was determined to be O.3~g/~I, which was within the
linear range for the assay. The TRAP assays of the early and late passage T1 cells showed
that there was no significant increase in the level of telomerase activity between early and
late cultures. Therefore this can be ruled out as a mechanism for the increase in
proliferations rate. If more time had permitted I would have liked to have examined other
aspects of late and early Tl cells, in particular if the telomeres had extended further in the
late passage cells.
3.6 No general loss of heterozygosity at genetic loci
encoding the cell cycle proteins involved in senescence
The cell lines were all assessed to find out if there was loss of heterozygosity at specific
loci. The loci chosen were those associated with the cell cycle proteins p21WAF,p57KIP2,
p53, pRB-l and INK4. There was no evidence of loss of heterozygosity at the p21WAF,
p57K1P2, p53 or pRB-lloci (Figure 3.13). However, it was noted that the fastest growing
clone T15 did show allelic loss at the INK4 locus (p15INK4B,p14ARFand pI6INK4A),despite
possessing a normal unmethylated p16INK4Agene (135). The improved proliferation rate of
HMCT15 relative to the other clones might therefore have been be due to reduced
expression of the p16INK4A or plSINK4Bproteins brought about by haplo-insufficiency.
However, surprisingly the levels of p14ARFplSINK4Band p16INK4Ain HMC TIS are similar
to early passage HMC cultures. Taken together, the data show that the HMC TERT clones
are genetically very stable and do not need to lose pl6INK4Ato develop and extend
replicative lifespan.
Figure 3.13 Loss of heterozygosity
Allelic analysis of genetic loci involved in cell cycle regulation and senescence. This
figure shows the retention of p53, pRB-l. p57KIP2 and p21WAF loci. However at the
INK4A locus there is loss of heterozygosity in T15. The arrows indicate the position of
each allele and the informative microsatellite illustrated is given above each panel next to
the locus name. Each of the markers was repeated three times and gave the same results as
shown here.
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3.6.1 Loss of INK4 in TERT 15
To further examine the importance of this loss of heterozygosity of the INK4 locus in T15
three cell line were transfected with E6 and E7 to see if this had an effect on the
proliferation rate of the cell line. The clones examined were T2, T4 and T15. The cell lines
were infected using a Puromycin resistant only or with E6 or E7 expression vectors. They
were infected with E6, or E7 or vector alone. The MPD for each cell line can be seen in
Figure 3. As can be seen in the graph the introduction of E6 and E7 has made only a slight
difference in the growth rate ofT2 and T4 and very little to TI5.
3.6.2 Discussion
E6 and E7 can improve the growth rate of slow growing clones slightly, but not T15
suggesting that the cell cycle controls may have been subtly altered in T15. However, the
growth rates of E6/E7 T2 ; E6/E7 T4 cultures growth rate did not match that of TI5,
suggesting that if the pRb/p53/p2I pathways are slightly more compromised in TI5 than
the other clones this does not account for the faster growth rate of TI5.
Figure 3.14 Growth rates from transfection with E6/E7
The three graphs below show the growth rates from T2 (A), T4 (B) and TIS (C) cells
transfected with E6, E7 or puromycin vector alone. These results are from one experiment
only.
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Figure 3.14 Growth rates from transfection with E6/E7
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3.7 Staining for P16
As discussed in Wootton et al in the immortalisation of keratinocytes there is also a slow
proliferation rate to start which then takes off. In keratinocytes this is due to the increase
and then decrease of p16. Western blot of p16INK4A were performed at different MPDs,
after the hTERT clones had bypassed senescence. The levels of p16 were measured by
June Munro and there was no direct correlation between MPD, growth rate and p16
expression. To ensure that the levels of p16 does not increase as the cells approach
senescence immunohistochemistry staining of human muscle cells was done at different
time points. As can be seen from figure 3.15 there is no marked increase or decrease in the
staining levels of HMCs compared to controls at different MPDs.
Figure 3.15 Analysis of p161NK4A
The western blot (A) was performed by Dr J Munro showing there is no increase in the
accumulation of P16. which is often seen in cells in culture. BIeR31 was used as a positive
control
Immunohistochemistry staining also demonstrated that there was no increase in p16 in
HMC as they approach senescence. B is cells at early passage while C is cells approaching
senescence. BICR6 (D) cells were used as a negative control since they do not express p16
and HeLa cells were used as a positive control.
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3.7. 1 Discussion
From these experiments it was determined that the proliferation rate in the hTERT clones
is unrelated to pI6INK4A.The difference in the clones growth rates was initially thought to
be due to the accumulation of pI6INK4A,as seen in keratinocytes(136). It has also been
shown in TERT-expressing epithelial cells that the cells will not bypass senescence unless
p16INK4Ahas been inactivated (137). Therefore it was encouraging to see that one of the
hTERT-expressing clones (T3) showed levels of p16INK4Alower than that of earlier
passaged cells. However there was no clear correlation between the levels of p16lNK4Aand
the proliferation rate. Also, although TIS has an allele missing in the INK4A locus, it did
not reduce the level of expression of p16INK4Acompared to the other clones. Dr J Munro
then sequenced three exons of the p16IN4Alocus and it was shown to be wild type and
unmethylated (P16INK4Ais often silenced by methylation). Although these results suggest
that there are no alterations in the pI6INK4A/RB pathway, we cannot rule out other
secondary changes. However there is no straight forward relationship between the growth
rates of each clone and the pl6INK4Astatus. Other cell cycle regulators were later examined
by Dr J Munro (Wootton et al, 2003), these included pISINK4B,c-myc and p21WAF. Again
these were not abnormal in their levels of expression.
3.8 TERT-expressing HMCs can regenerate striated
muscle in vivo.
The expression of hTERT has been reported not interfere with the differentiation
programme in HMCs without lifespan extension (138). The cells were first tested for their
ability to differentiate in vitro. The cells were grown on glass chamber slides and once the
cells had settled their medium was changed to 2% horse serum. The cells were then fixed
and stained with desmin using the standard protocol. As can be seen in Figure 3.16
myotubes with numerous nuclei can be seen. The numbers of positive fibres were not as
successful as hoped. When reviewing the literature it was suggested that telomerase is
switched off before myocyte differentiation can take place. This may have been the reason
for the poor success rate.
We then went on to test whether our cultures with extended lifespan could still differentiate
and re-constitute human striated muscle in vivo. For this part of the experiment I provided
the TERT expressing HMCs in culture medium and these were transported to Dr D Watt at
The Imperial College. Here they were transplanted into RAG-l mice (139) in which a
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localised area of trauma had been produced. A pervious attempt using SCID mice was
proven unsuccessful as they could not withstand the procedure.
T15 engrafted more efficiently, in keeping with its high proliferation rate in vitro. Figure
3.17 shows the presence of healthy mature muscle fibres in grafts from both T2 (Figure
3.16 and T15 (figure 3.16). In contrast, grafts of late passage control HMCs and ungrafted
controls (Fig 3.16 show no evidence of regeneration. The human grafts also stained
positively with a human specific spectrin antibody confirming their human origin (Figure
3.17) in contrast to the non-grafted controls and normal mouse muscle. The
submembranous staining pattern in the T2 engrafted muscle was observed in 38% of the
muscle fibres present in the graft close to the injection site and resembled that of normal
human muscle. Thus the HMC clones that display a considerable extension of proliferative
lifespan can still undergo fusion and re-constitute mature striated muscle, in vivo and these
observations are consistent with previous reports that telomerase expression does not
disrupt the differentiation programme of HMC cells (130, 138). Table 3.2 shows the
percentage of spectrin positive fibres in the grafts in normal muscle cell grafts and hTERT
muscle cell grafts.
Muscle Graft Number of spectrin-positive Percentage of spectrin-
fibres/total number of fibres positive fibres
Normal cultured human 26/105 24.8
muscle cells
HMCT2 312/1099 28.4
Table 3.2 Comparison of the number of fused muscle cells in xenografts of normal HMCs
and the telomerase-expressed HMC clone T2
Figure 3.16 In vitro differentiation of T15 stained with desmin
The figure shows the development of myotubes with multi nuclei within the cell. The
characteristic branching of the differentiated cells can also be seen. Arrows indicate the
multiple nuclei. Figure 3.16 B is a high power photograph of A.
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Figure 3.16 In vitro differentiation of T15 stained with desmin
Figure 3.17 H+E staining of mouse sections implanted with human muscle
cells
The figure show the results of experiments in which HMC clones T2 and TI5 were grafted
into the damaged muscle of irradiated RAG-I mice. Figure A-C shows hematoxylin and
eosin stained muscle grafts and control. A: T2 showing evidence of healthy muscle fibres,
B: TI5 showing healthy muscle fibres and C: un-injected control showing no mature Of
healthy regenerating muscle fibres.
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Figure 3.17 H+E staining of mouse sections implanted with human muscle
cells
Figure 3.18 Staining of Spec 1 on mice injected with human muscle cells
A: Graft ofT2, stained with a human specific anti-spectrin antibody. Showing evidence of
submembranous accumulation of the protein
B: Normal human muscle control stained with the same antibody
C: A control which was not injected with human cells showing no specific staining
D: Normal mouse muscle showing no specific staining
Arrows indicated spectrin positive fibres which have fused.
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Figure 3.18 Staining of Spec 1 on mice injected with human muscle cells
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3.8.1 Discussion
The TERT clones and HMCs were placed in a medium that encouraged differentiation (2%
horse serum in DMEM). The TERT clones (T2 and TIS) did not differentiate as efficiently
as the control cells (C2CI2). Examination of the literature suggests that when muscle cells
differentiate, telomerase is switched off. This may explain why the results for the in vitro
differentiation are not as successful as one would have hoped. Nonetheless they did
confirm that the cells were of the myogenic lineage. For this reason we still went ahead
with in vivo differentiation.
We collaborated with Dr D Watt who had developed the technique. It had been previously
established that muscle cells will unite with damaged myotubes in vivo, even between
species. This is a delicate experiment that requires immuno-compromised mice and a
defined area of trauma to undergo regeneration.
The result of the in vivo work was successful. The difference from the in vitro results may
be due to the fact that the artificial signalling is not adequate to overcome the continued
telomerase expression, while in the animal model, the cells can overcome this due a more
appropriate environment. The regeneration of the human muscle in the murine model was
localised to the site of injection. This localisation appears to be a common problem in the
use of cell therapy.
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4 Discussion
Research into DMD and the other muscle dystrophies has provided some insight into the
disease itself and novel therapeutic approaches to try and provide some form of treatment
for the disease. I have summarised the most promising therapeutic approaches which are
under investigation at present and discuss the merits and pitfalls of these approaches. I also
discuss the potential importance of my research in the context of existing therapeutic
approaches and provide an insight into the way forward.
4.1 Therapeutic attempts in DMD
The potential uses of gene and cell therapy were starting to be considered as treatments for
DMD by the late 1980's (140). In both cases the aim was the same i.e. replace the missing
gene product.
4. 1.1 Gene Therapy
4.1.1.1 Dystrophin gene replacement
At present the hope for a cure in a hereditary disease like DMD is based on gene therapy.
Indeed, this disease would appear to be an ideal candidate but there are major obstacles.
The dystrophin gene is the largest known, therefore obtaining a vehicle to deliver the full
size gene is a major problem (141). It has been achieved in the mdx mouse but only where
the expression was at a level 50 times greater than normal. Apparently this did reverse the
phenotype although this is controversial. Delivery of full length gene in a human at such
high levels would be difficult. To overcome this, a number of minigenes have been
developed as well as a naked DNA approach (142, 143). An unexpected difficulty
identified is that, although DMD sufferers do not express functional dystrophin, they do
express isoforms of the protein. This causes an immune response in the naked DNA
method (144).
The development of minigenes has focused on the production of small functional genes
which can correct the main problems in DMD. By analysis of mutations seen in Becker's
muscular dystrophy (BMD), a milder form of the disease, the important domains could be
recognised. These truncated forms of dystrophin were generated on an mdx mouse
background and the motor function of the animal assessed. This included the maintenance
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of strength and force and the presence of centrally located nuclei on histology. It was
concluded that the removal of the C-terminal domain (CT) or repeats 4-23 was compatible
with normal function (145).
However, although these minigenes are functional, transgenic animal studies have shown
that they cannot maintain muscle strength (146). The focus is again on larger constructs
and better delivery systems are now being investigated. Another major difficulty has been
the large target area and the multiple sites affected.
But the immunological problem still remains. The use of adenoviral vectors results in a
CD8+ T-cell mediated response and the DNA is often not incorporated into the host's cells
genome. The result of this is that the DNA is lost during the muscle turnover, which is
characteristic of DMD. Also retroviral vectors have been shown to invoke an immune
response and in some cases result in tumours derived from retroviral-producer cells. In an
effort to overcome these problems, a hybrid system of adenoviral and retroviral vectors has
been developed. It acts to stimulate the muscle cells to produce the retrovirus in vitro. To
overcome the immunological problem, a study has been performed on young mice (147).
There has been great development in the use of other strategies for gene therapy, including
the use of oligonucleotides to repair genetic mutations (148), and muscle-specific targeting
with adenoviral vectors (149). However all of these have their own limitations and none as
yet has been totally successful.
Another problem for gene therapy in DMD is the protocol which has been successful in
mice. The cells are first removed from the mouse and allowed to expand in vitro. Then the
gene is introduced and the cells are placed into the host (150). It has been documented that
in children with DMD the muscle cells have limited replicative capacity. Therefore the
transfer of this technique to clinical trials may prove difficult.
4.1.1.2 Utrophin overexpression
Utrophin has genetic similarities to dystrophin in that they both share the same C-terminal
domain binding proteins, namely the dystrophin associated protein complex (DAPC) (151).
It has been suggested that upregulation of utrophin might compensate for the deficiency of
dystrophin since this is normal in DMD. Due to the constant regeneration which occurs in
DMD, utrophin is increased in the muscle overall where it binds with components of the
DGC at the sarcolemmal membrane.
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Could utrophin act as a replacement for dystrophin? Utrophin has been shown to work in a
complementary fashion with dystrophin, i.e. as the levels of utrophin decrease as foetal
muscle develops the levels of dystrophin increases. Also in dystrophic muscle, it has been
noted that the levels of utrophin increase, compensating for the lack of dystrophin.
However as disease progresses, it cannot compensate for the normal levels of dystrophin.
Therefore the aim of this therapy is to induce overexpression of the protein (152) in the
hope that this could prevent the damage to muscle by playing the role of dystrophin.
Evidence to support this ideal came with the development of a transgenic mouse which
overexpressed utrophin but was breed on the mdx mouse. This animal had a less severe
phenotype than the mdx mouse, and showed less evidence of fibrosis and necrosis in the
diaphragm (153). The numbers of fibres positive for central nuclei (sign for regenerating
fibres) was also lower and the levels of serum kinase were close to normal. The increased
levels of utrophin in the mdx mouse would only have to be 2 to 3 times higher than in wild
type to illicit an effect (152). Also it was reported that the high ubiquitous expression of
utrophin has no toxic effect on the other organs. Drugs are now currently being developed
which will activate the expression of utrophin (154). Attempts have included using
glucocorticoids to upregulate levels of utrophin by post- translation mechanisms. This can
increase the level of utrophin by 40% in normal and dystrophic human muscle cells (155).
There has been many attempts at gene therapy focused on the expression of utrophin, and
adenoviral delivery of utrophin in muscle has been more successful in the mdx mouse than
with dystrophin (152). However as with dystrophin-directed gene therapies there are many
hurdles to overcome before this therapy could be used in humans.
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4.1.2 Cell therapy
Somatic cell therapeutic approaches have consisted of injecting normal myoblasts into the
muscle of affected boys, so-called myoblast transfer (156, 157). It was already known,
that in mdx mice, the dystrophic fibres would fuse with normal muscle fibres and it was
thought that the injection might therefore result in the expression of dystrophin in the child.
Partridge et al (158) had shown that in the mouse fusion did occur but he pointed out the
formidable problems involved in treatment of DMD, such as immune rejection and the fact
that all muscles were involved (159). Law (1988) had carried out similar experiments
using a different mouse mutant but he claimed that not only fusion occurred, but also that it
produced clinical improvement (160). This report led to enormous worldwide interest in
applying the technique to boys affected with DMD. Several trials were set up, using
normal myoblasts from fathers, brothers or histocompatible donors which were cultured
and then injected (157).
The definitive trial was carried out in 1995 by Mendell et al (157). Once a month for six
months, 19 of muscle was taken from the fathers or brothers of 12 boys with DMD. The
myoblasts were cultured and allowed to divide to yield 1 x106 cells. These were injected in
a grid formation at 55 sites, each 5mm apart, into one arm. In the other arm control
injections were carried out. Voluntary muscle strength was tested in each arm once a
month. The results revealed that myoblast transfer had no effect on muscle strength.
Immunosuppressive therapy produced no difference in strength between the control and
myoblast-injected arms. Investigation of dystrophin expression revealed no significant
differences between the myoblast-injected and control injected arms. Occasional
dystrophin positive fibres were identified, less than 1% of the total. One boy showed 10%
dystrophin-positive fibres but even he had no increase in muscle strength.
It was concluded that myoblast transfer failed to improve strength in patients with DMD.
The fact that several specific variables had to be considered was pointed out Le.
immunosuppression and the fact that the localisation site was massive. These workers did
not address the importance of another variable addressed in this thesis, Le. whether or nor
the transplanted myoblasts were capable of replicating in the child (157, 161). The results
of this trial put an end to the prospect that simple myoblast transfer techniques could be
beneficial to DMD patients.
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4.1.3 Tissue regeneration by embryonic stem cells and bone
marrow.
The importance of stem cells was first reported in the work of Till and McCulloch in 1961
(162). Their work on the haematopoetic system demonstrated that the bone marrow
contained clones of cells which could reconstitute the blood in patients exposed to
irradiation. Through the years this has been developed and bone marrow transplants are
common practice in the treatment of leukaemia and other haematopoeitc disorders. Now
there is a greater interest on developing cells of a more primitive origin, namely the
totipotent stem cells.
It has long been known that stem cells have three functions: to regenerate damaged cells, to
differentiate into new cell lineages and to self renew the population. It has been postulated
that by introducing stem cells into a diseased tissue, they may be able to repair the damage.
This is very promising, particularly in disorders such as neurological diseases where there
is no cell regeneration. To this end embryonic stem cells have been developed from the
inner cell mass of the blastocyst. (163). This provides stem cells which can act as totipotent
when introduced into the host. However at present not enough is known about the process
involved in the development of these cells to organs, and therefore manipulation of this is
not possible. Recent studies have suggested that the use of these cells may not be as
straightforward as once thought. Although stem cells are thought of as being
immunologically naive it has been demonstrated that once the cells start to differentiate
they switch on the MHC genes of the donor and therefore can be rejected by the recipient.
Also, in vitro these cells can develop neoplastic properties (164, 165).
Therefore although there is much hope for these cells as possible tools in curing many
disorders, this work is at a very early stage and much caution must be exercised in DMD.
As was first discovered by the use of bone marrow cells, there can be host rejection if the
donor and recipient are not matched. Therefore the use of embryonic stem cells may only
be completely risk free if, at birth the patient has the stem cells harvested from the
umbilical cord and stored. This is now being offered at some hospitals to new parents
(166).
4.1.3.1 Stem Cell Therapy
There are two types of stem cell: those derived from the embryonic blastocyst (embryonic
stem cells, ES) and those originating at various sites in the adult, like bone marrow (163).
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Both possess two abilities, i.e. maintenance of precursor cells with the ability to divide and
provision of such cells, which will then be able to differentiate. ES cells have not been
used in DMD.
Bone marrow, however, can give rise to myogenic progenitors which migrate into
degenerating muscle and regenerate it (167). Labelling of bone marrow mesenchymal cell
has shown that there is a subset of cells which can participate in myogenic differentiation.
These cells have been identified in the skeletal muscle of scidlbg mice two weeks after
muscle regeneration has been stimulated. There is also evidence of bone marrow-derived
cells in the skeletal and cardiac muscle of mdx mice after bone marrow transplantation.
This supports the idea that the haematopoietic cells can become myogenic and migrate to
the site of injury (168). Thus the hope of a bone marrow transplant as a potential therapy
seems very promising. However when a bone marrow transplant from a healthy mouse was
given to mdx mice there was no significant increase in the number of dystrophin-positive
fibres (169). Also, the quantification of dystrophin-positive fibres arising from the bone
marrow was difficult to determine, due to the presence of revertant fibres in the mdx
mouse. When the experiment was changed to use mdx4cv mice which have no positive
dystrophin fibres the outcome was not as successful. The percentage of positive-dystrophin
fibres averaged at 0.25%. peR analysis of the muscle showed that the repair by BM-
derived muscle cells did not exceed 1% (170, 171).
However recent developments have suggested that cells derived from bone marrow do not
in fact reconstitute new cell populations but fuse to existing cells. An example of this was
shown in bone marrow-derived hepatocytes. The bone marrow cells could repopulate the
liver of mice suffering from fum aryl acetoacetate hydrolase deficiency and could correct
the disorder. However, this was due to the fusion of bone marrow cells rather than the
development of new hepatocytes (172). This may be able to explain why the bone marrow
transplant was unsuccessful in the mdx mouse.
The way forward for stem cell therapy may lie in the purification of muscle precursor cells
which could then be implanted into patients (159). Early muscle cells have been purified
by preplating cells and selecting those which are desmin-positive (an early myogenic
marker). These cells have been shown to regenerate muscle after injection into a mouse
host. They seem to home to the site of injury more rapidly than bone marrow-derived cells.
The number of cells required to replace the damaged muscle still has to be determined,
however this approach remains promising.
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4.2 Lessons from animal models
4.2.1 The mdx Mouse
The most common animal model used in the study of DMD is the mdx mouse. This animal
was found to have a spontaneous, non-sense mutation in exon 23 (109, 121). Dystrophin is
absent as in the human, but the model does not show the phenotype of DMD. Muscle is
regenerated continuously and there is no influx of fibrous or fatty tissue. Also there is a
high incidence of revertant fibres, which express dystrophin. The affected skeletal muscle
appears to be in a constant state of successful regeneration.
To try and mimic DMD, there have been a number of new models developed, all based on
the mdx mouse. mdx2-5cv and mdx4cv have been generated by chemical mutagenesis as
has the mdxbsu-l- which has no utrophin. The mdx2-5cv and mdx4cv are characterised a
stop codon in exon 53 of the dystrophin gene. These models have no revertant fibres (173).
The mdx/utr-/- mice (also known as dko), have a more severe phenotype with marked
kyphosis. It is thought that these animals may die from respiratory failure at 20 weeks,
however at this point the muscles of the tongue are not strong enough to allow for feeding,
and there may be cardiac defects also (174). These models are closer to DMD but still do
not show the phenotype observed in the human DMD.
Mouse cells have telomeres up to three times as long as human cells and they have greatly
increased replicative potential. The fact that the mdxicu-l- is closer in phenotype to DMD,
may be due to the observation that, the normal phenotype in the mdx mouse is due to long
telomeres and the mice may have the ability to use utrophin to compensate for the lack of
dystrophin better than humans. The failure of the mdx mouse to display phenotype of the
disease has been recognised by scientists working in other fields (109). It has been
proposed that the poor results seen with the transplantation of BM-derived cells, may be
due to the mdx mouse having hypertrophic muscle and continuous regeneration (170).
This discrepancy between an animal model and a human disease has been observed in
other disorders. Heterozygote mouse models for many tumour suppressor genes show no
abnormality but, if the mutation is homozygous, the defects are lethal. These include
BRCA1, BRCA2, WT1, VHL and E-CAD (175). In other models, other factors can
compensate for the defect. This is seen in the mouse model for retinoblastoma. In the
human, heterozygosity for RB results in a predisposition for retinoblastoma, a hereditary
tumour of the eye. However in the mouse model, retinoblastoma does not develop because
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in mice, the p107 gene suppresses the development of the tumour (176). Mouse models do
not always replicate human disease even when the same germline mutation is present. In
the case of DMD, however, studies on the mdx mouse suggest that continual regeneration
may have the beneficial effect: this adds to the value of our work in extending the
replicative lifespan of skeletal muscle cells.
It recently has been suggested that there is another population of myoblasts, similar to the
satellite cells but with stem cell-like properties. When injected into mdx mice, these cells
show enhanced proliferation and it has been proposed that selecting for this population will
make the uptake of cells into the host graft more successful (159). These muscle progenitor
cells are now being used in gene therapy as it has been suggested that by using these cells
there is a better uptake of the gene into the muscle (177).
4.2.2 Immunosuppression and gene delivery
Recent advances with animal models have shown that the choice of immunosuppression
can be optimised and is of great importance in how well the graft takes (178, 179). The
importance of the immune response was highlighted during clinical trails for myoblast
transfer. It was shown that even when the donor and recipient were matched at the major
histocompatiblity locus, there was still the development of antibodies against dystrophin
and signs of immune rejection (180). Use of the patient's own cells in genetic
manipulation, however may overcome this problem. This underlines the importance of our
results.
The angle of injection or the use of enzymes which degrade the extracellular matrix might
improve migration (181). Delivery to multiple sites however still proves to be a great
problem. The replicative ability of the myoblasts, which was not considered, is likely to
have also been a major factor.
4.3 Importance of cell culture conditions
There has been a great interest in whether the culture conditions for the growth of the
muscle cells are optimal and how much a role this could play in successful cell therapy
approaches. This has also been debated in culturing of skin keratinocytes and breast
epithelium. It had been suggested that these cells could only be immortalised via
telomerase activation and removal of pI6INK4A/pRB pathway. However it has been shown
that these cells can be immortalised by telomerase alone, if the correct culture conditions
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are used (136). As can be seen from our results, the use of different media greatly
improved the lifespan of the hTERT-infected cells. It has also been suggested that the
levels of oxygen in incubators are too high and this can result in oxidative stress and lead
to damage to the chromosomes resulting in DSBs and senescence. To assess the
importance of this, other groups have changed the conditions in which they grow the cells.
It has been documented by Minamina et al (133) that hypoxic conditions can extend the
lifespan of vascular smooth muscle cells by activating telomerase and reconstituting
telomeres. It has also been suggested that the levels of oxygen in vitro can hinder the
replicative potential of lung fibroblasts. This leads to the suggestion that it is not only the
end replication problem that is regulating the length of telomeres but also oxidative
damage (132). To test this, we performed preliminary experiments of our hTERT-infected
muscle cells in low oxygen conditions. However our results were not conclusive and given
more time this would have been an avenue that I would have liked to explore.
4.4 Previous attempts at extension of lifespan of human skeletal
muscle
Decary et al 2000 has already shown that human myoblasts have a limited proliferative
capacity and low level of nuclear turnover. They went on to measure telomere length in
dystrophic patients of various ages. They showed that at the age of 2 yrs the myoblasts of a
patient with DMD were already 14 times shorter than a normal child of the same age (119).
However there have been suggestions that it is not in fact replicative senescence which has
caused the onset of the disorder but rather the inability of the dystrophic satellite cells to
differentiate (120, 182). This explains the failure of myoblast transfer but fails to answer
why the absence of dystrophin in the mdx mouse did not prevent the constant regeneration
and differentiation seen in this model. A way to resolve this conflicting view and
potentially create a better mouse representation of DMD would be to cross the mdx mouse
with the short telomere mouse. If this new cross showed the progressive muscle wasting,
with necrosis, fatty tissue influx and premature death, then replicative senescence would be
the contributing factor. If this cross did not show the phenotype of DMD then the role of
failure to differentiate could be further investigated.
Despite these conflicts of ideas, other groups have previously attempted to immortalise
human skeletal muscle. In 1999 Louchmuller et al reported the extension of lifespan of
human myoblasts due to the expression of E6 and E7 genes of the human papillomavirus.
The use of these DNA tumour viruses did extend the lifespan, but they failed to report if
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the cells' karyotype had changed, if the infection had resulted in any malignant
transformation or if in vivo differentiation was possible (183). A year later Seigneurin et al
reported that it was not possible to immortalise DMD muscle with SV40 T-antigen (Tag),
but the lifespan could be extended somewhat. It was only when the Tag-transformed cells
were also transfected with hTERT that the cells could bypass senescence. Again absence of
malignant transformation was not reported (130). Further work suggested that the lifespan
of muscle cells could be extended slightly by transfection with hTERT, but the group did
not see the same extension as in our study. However, interestingly, they did have some
extension with DMD muscle cells, and these cells were able to constitute muscle fibres in
scm mice (138).
We have shown here that the expression of telomerase can result in the extension of
lifespan of HMCs from two separate donors. These cells have bypassed senescence
without any malignancy and can reconstitute human muscle fibres in mice. The
introduction of telomerase has resulted in the extension of telomere (Dr K Gordon,
Wootton et aI, 2003) without reduction in p16 levels, or methylation of p16 or an increase
in c-myc (Dr J Munro, Wootten el al, 2003). We have demonstrated that it is possible to
extend the lifespan of HMCs with hTERT alone, providing the correct culture conditions
are used.
4.5 Final summary and future work
The nature of the disease has been analysed by the study of microarrays of DMD muscle
compared to normal skeletal muscle. Interestingly of the 110 genes examined more were
overexpressed than underexpressed. Naturally dystrophin was underexpressed, however,
gene coding for immune response signals, and those associated with regeneration were
overexpressed (184). Therefore the use of gene therapy may have to be readdressed to
accommodate the newly detailed progression of the disease and the numerous factors
involved.
The fast growth rate of TIS, compared to the other clones, was of great interest, and I
would have liked to examine this further. During the course of the project it was
discovered that the only difference between TIS and the other cell lines, was it had an
allele missing at the INK4A locus. Although this did not affect the levels of p16, it may
have allowed selective advantage over the other clones. The question as to why this clone
has achieved such a growth rate will not be answered until microarray analysis of this
clone compared to other clones and normal HMCs is carried out. If more time had
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permitted and there was limitless resources I would have liked to examine the hTERT
clones via DNA array, micro-array and eventually proteomics. There may be subtle
differences between each clone, and this would fully answer the question, how has the
introduction of telomerase into the cells altered them.
I believe that this technique for immortalisation could be perfected further and I wished I
had more time to explore the use of low oxygen culture conditions. It is now becoming
evident that cellular senescence is more complicated than first thought. The end replication
problem is not the only mechanism controlling the fate of a cell lifespan, and there is
increasing evidence that oxidative damage initiating the DNA repair mechanism also play
a role. I think that by adapting culture techniques, we may see better results.
This work has provided a mechanism by which long-lived cell lines can be produced for
use in all aspects of musc1e research. Obtaining a biopsy is invasive and normal muscle has
a limited replicative lifespan, so that this will hopefully provide a resource for many
researchers.
The development of immortal muscle cells may not only provide valuable tools for
research but may also in the future provide strategies for therapy. Although our cells were
permanently transfected with hTERT, this could be refined by using a ere recombinase
and hTERT flanked by 10xP sites (89). This would allow the hTERT to be introduced and
then removed once the telomeres had been extended. This would be beneficial as it is
understandable that for clinical use there would be concerns about transplanting a
telomerase-positive cell line into a child. Using this system, the cells could be taken by
biopsy, transfected with hTERT, their telomeres extended, and then the hTERT removed.
At this point the cells could be reintroduced into the patient and allow for more successful
gene therapy. Therefore if time and resources had allowed I would have liked to try this
technique to immortalise muscle from a BMD patient and from a DMD patient.
Wither you believe that the onset of DMD is due to an inability for cells to differentiate, or
if it is due to lack of replication by the muscle cells, it cannot be argued that this is a
complex disease which will not be cured by one line of therapy alone. It will take
collaboration from gene, cell and stem cell therapy to find a cure.
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Telomerase Alone Extends the Replicative Life Span of
Human Skeletal Muscle Cells Without Compromising
Genomic Stability
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ABSTRACT
Continuous cycles of muscle fiber necrosis and regeneration are characteristic of the muscular dystrophies,
and in some cases this leads to premature replicative senescence of myoblasts in vitro. The molecular mech-
anism of senescence in human myoblasts is poorly understood but there is evidence to suggest that telomeric
attrition may be one of the ways by which this is achieved. We report here, for the first time, the extension
of normal human skeletal muscle cell replicative life span by the reconstitution of telomerase activity. The
telomerase-expressing cells show no features of transformation in vitro and have stable genomes with diploid
karyotypes, do not express exceptionally high levels of e-myc and have wild-type, unmethylated CDKN2A
genes. In vivo, they regenerate to repair muscle injury in immunosuppressed RAG-! mice. This work suggests
that telomerase expression to repair short telomeres may aid the expansion of diploid human muscle cells and
consequently attempts at gene therapy for muscle diseases.
SUMMARY OVERVIEW
In the muscular dystrophies, continuous cycles of muscle
damage and regeneration cause the replicative capacity of
the myoblasts to decline and this may be linked to telomeric
attrition. Because premature myoblast senescence may frus-
trate attempts at gene therapy, we tested the ability of telo-
merase to elongate muscle cell telomeres and extend their
replicative life span. We report here, for the first time that
telomerase extends the life span of normal human skeletal
muscle cells without transforming the cells or compromis-
ing genomic stability. The cells can regenerate striated mus-
cle when injected into immunosuppressed mice. These re-
sults suggest that the expression of telomerase may be a
useful aid to gene therapies for muscle diseases, especially
the muscular dystrophies.
INTRODUCTION
HUMAN TELOMERES are composed of tandem repeat(TTAGGG)n sequences of DNA. In cells that are "im-
mortal," such as the human germline, a stable telomere length
is maintained through the action of telomerase (Counter, 1996).
Early in human development, telomerase is downregulated in
most somatic cells, and this, at least in part, results in the pro-
gressive shortening of telomeres that culminates in replicative
senescence (Harley et al., 1990; Wright et al., 1996; Bodnar et
al., 1998). In the absence of extensive cell division in vivo,
telomeres do not shorten, as exemplified by the fact that telo-
mere length remains constant in telomerase-negative tissues,
such as the brain and striated muscle (Decary et al., 1997).
When human muscle cells (HMC) are grown in vitro, the cells
replicate for a limited number of population doublings, during
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which time telomeres shorten until, although the cells remain
viable, they will no longer divide (Decary et al., 1997). Prolif-
erative capacity and telomere length have been correlated in hu-
man satellite cells and an age-related decline in each has been
shown (Decary et al., 1997).
In patients with Duchenne's muscular dystrophy (DMD), the
fatal loss of muscle is caused by the decline in muscle regen-
erative capability; this may be a consequence of premature
replicative senescence. The role of telomeric attrition in the
premature senescence of DMD myoblasts is controversial (De-
cary et al., 2000; Oexle and Kohlschutter, 2001) but telomere
shortening could explain the premature senescence of the HMC
cultures from these patients (Webster and Blau, 1990).
There is considerableinterestin developing an adequate gene
therapy strategy for DMD and it was recently shown that wild-
type dystrophincould correctthe muscle phenotypeof the DMD
laboratory model (mdx mouse) when introduced using an adeno-
associated virus carrying dystrophin minigenes (Wang et al.,
2000a). However, murine cells have long telomeres (Kipling
and Cooke, 1990), and therefore, the mdx mouse muscle cells
are unlikely to experience critical telomere loss during a nor-
mal life span. As a consequence, the premature replicative
senescence characteristic of human DMD muscle cells may not
occur. This may explain why mdx mice only exhibit the de-
generative phase of the human disease in the early stages of life
and from then on seem capable of continuous regeneration.
Attempts have already been made to extend the replicative
capacity of myogenic cells using DNA tumor viruses (Morgan
et al., 1994; Lochmuller et al., 1999; Seigneurin-Venin et al.,
2000b) but such approaches cannot be countenanced for human
transplantation. Inactivation of p53 by the viral genes, even if
expressed transiently, would likely create genetic instability
(Kastan et al., 1991; Yin et al., 1992). It might be predicted
that as myoblasts are a similar cell type to fibroblasts, they
should be readily immortalized by the expression of the cat-
alytic component of telomerase, hTERT, without sustaining
chromosomal alterations or transformed properties (Bodnar et
al., 1998; Vaziri and Benchimol, 1998). However, not all groups
report the successful immortalization of human fibroblasts us-
ing this approach (O'Hare et al., 2001). Furthermore, attempts
to reconstitute telomerase by ectopic expression of hTERT did
not result in extension of replicative life span in either normal
or DMD myoblasts (Seigneurin-Venin et al., 20ooa).
Here, using a different culture medium and protocol to that
used above, we describe the successful extension of the life
span of human skeletal muscle cells for more than 120 mean
population doublings (MPDs) by means of telomerase recon-
stitution and show that these cells are genetically stable, non-
transformed, and have the ability to regenerate muscle in the
RAO-l mouse.
MA TERIALS AND METHODS
HMC culture and retroviral infection
The human muscle satellite cell cultures were established
from a biopsies taken from a 23-year-old male (line 1) and a
28-year-old female (line 2) by explant culture using special
techniques to prevent the outgrowth of fibroblasts (Edington et
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al., 1995). The culture medium was Dulbecco's modified Ea-
gle's medium (DMEM) containing 20 mM HEPES, glutamine,
antibiotics, and 10% vol/vol fetal bovine serum. The cells were
then released from the culture vessel using O. I% trypsin and
0.0 I% ethylenediarninetetaacetic acid (EDTA) and designated
MPD 0 cells. The MPDs were calculated as previously de-
scribed (Munro et al., 200 I). The cells were confirmed as
HMCs by their immunoreactivity with desmin antibodies (see
below) and were routinely passaged at 5 X Ier cells per 5 cm.
diameter dish (Nunc or Falcon). The HMCs were infected with
the pBabeNeo and pBabeEst2 retroviruses (Vaziri and Benchi-
mol, 1998) as described previously (Munro et al., 2001) and
the infected cells were selected with 200 ILg/ml 0418. The
0418 was removed once the mock-infected plates were dead.
In the pBabeEst2 retroviral vector hTERT is transcribed from
the retroviral LTR (Vaziri and Benchimol, 1998). All experi-
ments were performed with the pBabeEst2 (hTERT)-infected
myoblast clones when they had completed between 51 and 68
MPDs after infection with the retroviruses. Senescent HMC cul-
tures were defined as those that incorporate bromodeoxyuridine
(BrdU) into 5% of the cells, or less in 48 hr (Stein, 1985) and
failed to undergo 1 MPD in 4 weeks. Some cultures were also
stained for the presence of the senescence associated f3-galac-
tosidase as described by Dirnri and coworkers (Dimri et al.,
1995).
BrdU labeling and detection
BrdU labeling was carried out exactly as described previ-
ously (Munro et al., 200 I).
Senescence-associated f3-galactosidase assay
Senescence-associaed f3-galactosidaseassay was carried out
by the method of Dimri and coworkers (Dimri et al., 1995) as
modified by Munro and coworkers (Munro et al., 200 I), except
that the assay was carried out at pH 5.8 instead of 6.0. pH 5.8
gave superior staining in the senescent HMCs.
Agar colony assay
The ability of the cells to form colonies in suspension was
tested by suspending the cells in 0.4% agar (D1FCO Bactoagar,
Detroit, MY) in DMEM containing 20% vol/vol fetal bovine
serum at a density of 105 ceIIs per 5-cm diameter dish.
Low serum assay
The cells were plated in DMEM containing 0.2% vol/vol fe-
tal bovine serum at 5 X 104 cells per 3-cm diameter dish for 3
weeks prior to the commencement of the experiment because
human cells can take 10-14 days to become fully quiescent
(Seshadri and Campisi, 1990). The cells were disaggregatedand
counted weekly and the MPDs calculated as detailed above.
HeLa ceIIs were used as a positive control line and normal HMC
cells at early passage were used as negative controls.
Immunohistochemistry
CeIIs were grown on chamber slides and washed three times
in phosphate-buffered saline (PBS). The slides were then fixed
in acetone at 4°C for 20 min and air-dried. The cells were
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blocked with 2% horse serum in PBS for 30 min. The slides
were incubated for 60 min at room temperature with a mouse
monoclonal antibody directed against desmin (clone D33, at a
dilution of I: lOO,Dako Corp., Carpinteria, CA). After washing
with PBS the cells were incubated with secondary and tertiary
antibodies from the avidin-biotin complex (Vectastain Peroxi-
dase Mouse IgG ABC kit, Vector Laboratories Inc.,
Burlingame, CA) per the manufacturer's instructions and
stained with 3,3' diaminobenzidine (DAB).
Muscle sections were blocked with 2% horse serum in PBS
for 30 min and were incubated with the primary antibody spec-
trin (NCL-SPEC2, at a dilution of I: I 00; Novocastra Labs,
Newcastle upon Tyne, UK) overnight at 4°C. The slides were
washed and stained using the Vector MOM Immunodection Kit
as described (BMK-2202, Vector Laboratories Inc.) and stained
with DAB.
Western blotting and antibodies
This was performed essentially as described by Munro and
associates (Munro et al., 1999,2001). One hundred micrograms
of protein was subjected to electrophoresis on 10% (c-rnyc) or
17% (CDKls) gels. Primary antibodies were: p 16lNK4A (C-20;
Santa Cruz Biotechnology, Santa Cruz, CA), ERK2 (BD Bio-
sciences, Heidelberg, Germany) and c-rnyc (N-262; Santa Cruz
Biotechnology). The SV40-immortalized human keratinocyte
line SV6-1 HFK was used as a positive control for p 16INK4A
and the human squamous cell carcinoma line BICR31 as a neg-
ative control. BICR31 harbors a homozygous deletion of the
INK4A locus. The HaCaT line is an immortal human skin ke-
ratinocyte line that expresses high levels of p15fNK4B.The hu-
man squamous cell carcinoma line BICR78, which does not ex-
press pl5INK4B mRNA, served as a negative control for
p15INK4B.HFF UV are human fetal skin fibroblasts irradiated
with 8 mJ of ultraviolet light from a Stratalinker 2400 (Strata-
gene, La Jolla, CA) and harvested 16 hr later.
p](JNK4A PCR and DNA sequencing
The sequencing of exons la, 2, and 3 of the INK4A locus
was performed as described previously (Munro et al., 1999).
Bisulfite modification of pl 61NK4A and PCR
Genomic DNA was modified using the CpGTMDNA Mod-
ification kit (Intergen Company, Oxford, UK) following the
manufacturer's instructions wi th the following alterations. DNA
modification reagent I included urea (Paulin et al., 1998) and
the modified DNA was eluted in 40 ILl of 10 mM Tris pH 7.5,
0.1 mM EDTA.
PCR was carried out on 1 ILl of modified DNA using the
primers of Bauer and associates (Baur et al., 1999). PCR con-
ditions were according to manufacturer's instructions using Im-
molase DNA Polymerase (Bioline Ltd., London, UK) and ei-
ther 1.75 mM MgCh (methylated modified form primers) or 2
mM MgCI2 (un methylated modified form primers) depending
on primer sets used. The PCR cycles were 95°C for 7 min fol-
lowed by 35 cycles comprising 94°C for 30 sec, 60°C (methy-
lated modified form primers) or 58°C (unmethylated modified
form primers) for 30 sec and noc for 30 sec. There was a nec
extension time for 7 min. Products were sequenced using se-
1475
quencing conditions as described (Munro et al., 1999). The hu-
man squamous cell carcinoma line SCC-15 has a completely
methylated p 16INK4Agene promoter and the DNA from this line
served as a control for the methylated PCR primers and as a
negative control for the unmethylated ones. DOK is a human
keratinocyteline derived from a squamous dysplasia of the oral
cavity and expresses a mutant pl6INK4A protein. DOK DNA
was therefore used as a positive control for the unmethylated
PCR primers and as a negative control for the methylated ones.
Telomere length measurement
This was performed as described previously (Munro et al.,
2001), except that the blot was hybridized with a radiolabeled
oligonucleotide probe (TTAGGG)) at 42eC and subsequently
washed to a stringency of 6xSSCIl % sodium dodecyl sulfate
(SDS) at 42°C. The telomere lengths were measured as de-
scribed (Munro et al., 200 I).
Telomerase activity
Cellular extracts were prepared and assayed for telomerase
activity using the TRAPeze kit (Intergen, Company, UK) fol-
lowing the manufacturer's instructions.
Microsatellite analysis
Total reaction volumes were 10 ILl containing40 ng genomic
DNA, 10 mM Tris-HCl, pH 8.3, 50 mM KCl, 1.5 mM MgCl2,
10% dimethyl sulfoxide, I ILM of each oligonucleotide primer,
200 ILM of each deoxynucleotide triphosphate, 0.4 ILl of
[a32P]dCTP (24.7 kBqlILI) and 0.5 units of Taq polymerase
(Advanced Biotechnologies, Epsom, Surrey, UK). Reactions
were subjected to an initial denaturation step of 5 min at 94°C,
followed by 30 cycles of 30 sec at 94eC; 30 sec at 55-65°C;
and 30 sec at noc, and a final extension step of 7 min at noc.
Samples were electrophoresed on 4-10% polyacrylamide gels
under denaturing conditions. Gels were dried then exposed to
x-ray film to visualize the resolved reaction products. The fol-
lowing markers were used. Dl7S1353B (p53), D 13S153 (pRS),
011 S922 (p57), D6S1051 (p21), and D9S 1870 (INK4A).
Cytogenetics
Medium was changed 24 hr prior to harvesting to enhance
cell division. Demicolchicine (0.01 ILg/ml) was added for 4 hr
to arrest the cells in metaphase. Metaphases were harvested and
G-banded using conventional techniques.
Induction of regeneration in host muscle and
implantation of cells
Irradiated RAG-l mice were chosen as hosts to receive the
cellular implants because they can accept xenografted cells
without immune rejection of the implanted cells. Under these
conditions the grafted cells are more likely to regenerate mus-
cle after myotoxicity (Watt et al., 1982; Wakeford et al., 1991).
Barium chloride, an agent that is myotoxic and causes the mus-
cle fibers to degenerate was administered as described (Cald-
well et al., 1990). Forty-eight hours after bari um chloride ad-
ministration the right tibialis anterior (TA) muscle of host mice
was implanted with 3 X IO 5 cells as described (Gibson et al.,
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1995). Six TA muscles received HMCT15 cells, two HMCT2
cells, and 3 were implanted with control human muscle cells.
Twenty-fivedays after implantation of the cells, recipients were
sacrificed, the TA muscle removed and frozen sections pre-
pared. Sections were stained with hemotoxylin and eosin or by
the immunocytochemical detection of spectrin (see above). The
number of spectrin positive fibers, indicative of muscle cell fu-
sion, were quantitated by examining at least five fields adjacent
to the injection site. Only muscle fibers that were positive for
spectrin on all sides were considered positive. At least ] 000
cells were scored per sample.
RESULTS
Extension of replicative life span of skeletal satellite
cells by hTERT expression
Skeletal HMCs were obtained from needle biopsies of patients
with no neuromuscular disease. After 5 MPDs HMC line 1 was
infected with either a retrovirus containing hTERT or with the
neomycin-selectable marker alone and HMC line 2 was similarly
infected after 25 MPDs. The mass cultures or clones were then
selected on G418. Both the HMCNeo mass cultures senesced af-
ter approximately 37 MPDs but the corresponding hTERT-in-
fected cultures have currently extended their life span to more
than 60 MPDs (HMC line I, Fig. la) and more than 57 MPDs
(HMC line 2, Fig. Ib). The senescent cultures of both HMC lines
contained predominantly flat cells that expressed the senescence-
associated .a-galactosidase (Fig. le), whereas the corresponding
TERT-expressing HMC cells were predominantly composed of
small, spindle-shaped cells that did not express senescence-asso-
ciated .a-galactosidase (Fig. Id). Three neo- (NEOI, NE02, and
NE03) expressing and five hTERT- (TERTI, TERT2, TERTI,
TERT4, and TERTl5) expressing clones were studied further
(Fig. 2). After 21-28 MPDs, all the Neo clones had a low BrdU
incorporation rate over 48 hr (Fig. 2a) and stopped proliferating
(Fig. 2a). In contrast, all five of the HMCTERT clones had a
higher BrdU incorporation rate and one clone, HMCTI5, was
comparable to the immortal HeLa cell line control (Fig. 2b). Four
of the five HMCTERT clones bypassed senescence immediately
(Fig. 2a) and have now achieved more than 120 MPDs. The TERT
clone HMCT1, displayed a slowed proliferation at the same time
as the Neo control clones and incorporated BrdU into only 25%
of the population in 48 hr but after several weeks it also escaped
senescence (Fig. 2a), consistent with a requirementfor a secondary
alteration in this clone. All of the TERT-infected HMC clones,
including HMCT] possessed robust telomerase activity, as as-
sessed by the TRAP assay in contrast to the Neo-infected clones
(Fig.3a).
Telomerase extension of proliferative life span is not
always associated with TRF length maintenance
It was important to establish how telomerase extends prolif-
erative life span, because the ability to repair short telomeres
will be important for gene therapy. After 5 MPDs in vitro, the
HMCs had average TRF lengths of 8 kb, which had shortened
to 6 kb in those approaching senescence. This is similar to the
length at senescence previously reported (Decary et al., 1997)
and somewhat longer than that reported for senescent fibro-
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blasts (Harley et al., 1990). The signal intensity of the TRF
smear also decreased upon senescence.
It can be seen from Figure 3b that three of the four hTERT-
expressing clones that bypassed senescence had TRF lengths
equivalent to, or longer, than in the young HMC cultures and
had a much stronger TRF signal. Clone T3, however, reached
at least 88 MPDs and had an average TRF length less than that
in the near-senescent mass cultures of the neo controls (Fig.
3b). There are precedents for this finding (Zhu et al., 1999;
Ouellette et al., 2000), which have been attributed first to the
ability of cells to retain capped and functional telomeres, even
when TRF are short (Zhu et al., 1999) and second, to the re-
cruitment of telomerase to the shortest telomeres (Ouellette et
al., 2000). The latter is thought to occur when TERT transgenes
become methylated and the telomerase acti vity decreases (Ouel-
lette et al., 2000). In any event, our results show that the
proliferative life span of HMCs can sometimes be extended
without the complete maintenance of average TRF length. Fur-
thermore, there was no correlation between the average TRF
length of each clone and its growth rate (Figs. 2a and 3b). In
particular, clones HMCTl5 and HMCT4 had the longest aver-
age TRF lengths but had very different growth rates.
Telomerase extension of proliferative life span is
dependent on the culture conditions
Previous studies of telornerase-expressng HMC cells cul-
tured in the Ham's FlO-based MCDB 120 medium failed to de-
tect an extension of replicative life span (Seigneurin-Venin et
al., 2000a). The retroviral vectors used by Seigneurin-Venin
and ourselves were essentially identical and led to telomere
elongation in some of the experiments of Seigneurin-Venin and
associates (Seigneurin- Venin et al., 2000b), so the telomerase
transgene was functioning normally in their experiments. How-
ever, one recent paper has highlighted the importance of cul-
ture conditions in the successful immortalization of several hu-
man cell types with telomerase alone (Ramirez et al., 200 I).
To test whether the difference between our results and those of
Seigneurin- Venin and coworkers (Seigneurin- Venin et al.,
2000a) could be because of the choice of culture medium, we
transferred normal HMC cells into Ham's FlO after 25 MPDs,
HMC T2 after 70 MPDs, and HMC TI5 after I 15 MPDs. The
normal HMCs grew through a further 4 MPDs in FlO medium
but showed a considerably truncated replicative life span when
compared to the same cells cultured in DMEM (Fig. 4a). In-
creasing the fetal bovine serum concentration from 10-20% in-
creased the replicative life span by 2.5 MPDs in both types of
media (data not shown). Both the telornerase-expressirg clones
underwent senescence after 6 (HMCT2; Fig. 4b) and I MPDs
(HMCT15; Fig. 4c), respectively, after transfer into Ham's FlO
and this result was not influenced by the fetal bovine serum
concentration. These results may explain the discrepancy be-
tween our results and previous reports by others.
The proliferation rate in TERT-expressing HMC
clones which bypass senescence is unrelated to
c-myc, pJ6INK4A, pJSINK4B, or p21wAF levels
The HMCTERT clones differed in their proliferation rates
but all were less than that of early-passage HMC cultures (Fig.
2a). A similar phenomenon has been noted in TERT-express-
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FIG. 1. Human skeletal muscle cell (HMC) cultures expressing high levels of telomerase show an extended replicative life
span. Growth curves of HMC mass cultures derived from two individuals and infected with either pBabeNeo alone or pBabeEst2
after 5 (line 1) (a) or 25 (line 2) (b) mean population doublings (MPDs). In both cases the replicative life span of the TERT-in-
fee ted mass cultures (red squares) has been extended well beyond the normal life span of the controls (blue diamonds) and the
cultures are still proliferating. Staining of the Neo-control HMC line 2 cultures after 37 MPDs for senescence-assOc(lted tJ-galac-
tosidase shows numerous large flattened cells that stain positively and appear blue on the photograph (c) but in contrast the TERT-
infected HMC cells showed few positive cells (d).
ing human keratinocytes that have bypassed senescence (Dick-
son et al., 2000; Ramirez et al., 2001), where the slow prolif-
eration rate was attributed to an accumulation of the cyclin-de-
pendent kinase inhibitor (CDKI), p 16!NK4A. When the
TERT-expressing keratinocytes increased their proliferation
rate, p 161NK4Awas lost or downregulated(Dickson et al., 2000).
In other culture systems also, TERT-expressing epithelial cells
senesce, unless p16!NK4Ais inactivated (Foster et al., 1998;
Kiyono et al., 1998).
We measured the levels of p161NK4Ain HMC mass cultures
and clones (Fig. 5a). The hTERT-expressing HMC mass cul-
tures increased p16!NK4Aexpression until they proliferated be-
yond the normal senescencecheckpointoF 30 MPD, whereupon
pJ61NK4Awas downregulatedto early-passage levels in the mass
cultures. Two of five HMC clones (HMCT3 and HMCT4)
showed less p 161NK4Aexpression than the early-passage
hTERT-expressing cells but unlike the situation with ker-
atinocytes (Dickson et al., 2000), there was no clear relation-
ship between the levels of pl61NK4A and the clonal prolifera-
tion rate. To test the integrity of the p161NK4Agene directly, we
sequenced the three exons of p 161NK4Ain all four of the HMC
clones and found it to be wild-type (data not shown). As
p 161NK4Ais often silenced by methylation (Merlo et al., .1995),
especially in vitro (Foster et al., 1998), we also performed
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FIG. 2. Telomerase-expressing human muscle cell (HMC)
clones show variable growth rates. a: Clones of pBabe Neo- and
pBabeEst2-infected HMC cultures from the experiment shown
in Figure 1. The number of each clone is indicated on the graph.
All the Neo-infected clones senesced after 21-28 mean popula-
tion doublings (MPDs), whereas the TERT-infected clones have
so far completed between 45 (HMC Tl) and 125 (HMC TIS)
MPDs. b: The incorporation rate of bromodeoxyuridine (BrdU)
into the different HMC clones and cultures shows that the dif-
ferences in culture growth rates in (a) can largely be explained
by differences in the size of the proliferating fraction and hence
the extent to which senescence is blocked.
bisulfite modification/sequencing of the genomic DNA and
four of the HMC clones contained unmethylated pl61NK4A
genes (Fig. 5b). We cannot rule out other secondary alterations
that may have affected the pI6INK4A/pRb pathway in the HM-
CTERT clones but there appears to be no straightforward re-
lationship between the proliferation rate of each clone and
pJ61NK4A status. The p151NK4Blevels were also sustained in
the HMCTERT mass cultures that had bypassed senescence
and in most of the HMC clones (Fig. 5a). HMCT4 again
showed the lowest levels of this CDKI and was one of the
slower growing clones (Fig. 2a). Therefore, the levels of
plSINK4B in the HMCTERT clones do not explain the varia-
tion in growth rate. There was also no relationship between
clonal growth rate and the levels of p2l WAF or p53, as the
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FIG. 3. Human muscle cells (HMCs) infected with pBabeEst2
express telomerase and generally maintain or extend average
TRF lengths. a: TRAP assays performed on the HMCNeo and
HMCTERT mass cultures and clones showing robust telo-
merase activity in all the cultures that bypassed senescence.
The Neo 3 clone illustrated was representative of six such
clones and was negative for telomerase. The lower arrow rep-
resents the internal standard product, which is used to check
for adequate polymerase chain reaction (peR) conditions.
CHAPS is the buffer alone negative control; TSR8 is the kit
positive control; HJ indicates the heat-treated control for each
sample. b: TRF Southern blot showing that the average TRF
length of the HMCNeo mass culture declines with serial cul-
tivation. This trend was progressively reversed in the mass
cultures infected with pBabeEst2 (HMCTERT). The HMC-
TERT mass culture and all of the clones (except HMCT3) at
least maintained average TRF lengths at presenescent levels.
Clones HMCT4 and HMCTlS extended their TRF lengths to
greater than presenescerr levels.
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FIG.4. Human muscle cells (HMCs) show a reduced replica-
tive life span in Ham's FlO medium and cannot be immortal-
ized with tel om erase alone. a: HMC line 2 was cultured in Dul-
becco's modified Eagle's medium with 10% fetal bovine serum
and after 25 mean population doublings (MPDs), either kept in
Dulbecco's (squares) or transferred to Ham's FlO (diamonds).
b: Clone HMCT2 growth was compared in the two media as
in (a) exceptthat the cells were transferred into FlO at 70 MPDs.
Symbols are as in (a). c: Clone HMCTl5 was compared in the
two media as in (a) except that the cells were transferred into
FlO at liS MPDs. Symbols are as in (a).
fastest growing clone, HMCTIS, had the most p2IwAF. The
levels of p53 were also examined and there was no evidence
of altered expression (data not shown). Although not entirely
conclusive, together with the p21 WAFdata, this result suggests
an absence of p53 mutations.
Another issue of importance when considering the use of
hTERT-expressing HMC cells in the treatment of human mus-
cle disease, is the status of the proto-oncogene c-myc, which
when upregulated can bypass the p161NK4Acell cycle check-
point (Alevizopoulos et al., 1997) and upregulate endogenous
telomerase levels (Wang et al., 2000b). Moreover, it is thought
that the upregulatim of c-myc may be responsible for the in-
ability to extinguish telomerase activity in TERT-immortal-
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ized mammary cells after removal of the TERT transgene
(Wang et al., 2000b). We therefore examined the levels of c-
myc protein in our clones. We found that the levels of c-myc
were approximately threefold higher in the HMCTERT mass
cultures once they had bypassed senescence and the HMC-
TERT clones expressed 1.7- to 6.0-fold more c-myc than the
HMC controls. However, the levels of c-myc in HMCTlS
were still 2- to IS-fold lower than the levels found in the im-
mortal cancer lines HT1080, Jurkat and HeLa (Fig. 5c). Fur-
thermore, there was no relationship between c-myc levels and
the proliferation rate of each clone (Fig. 2a). Therefore,
the proliferatim characteristics of the various HMC clones
expressing telomerase are not explained by their c-myc
status alone.
TERT-expressing HMC clones bypassing senescence
are cytogenetically normal
Human fibroblasts immortalized by the ectopic expression
ofhTERT are karyotypicallynormal and retain cell cycle check-
point function (Jiang et al., 1999; Morales et al., 1999) and
HMCs expressing hTERT must also display these characteris-
tics, if they are to be a useful adjunct to gene therapy.
After 50-70 MPDs all five of the hTERT expressing HMC
clones had a modal chromosome number of 46. The G-banded
karyotype of HMCTl~ 'Shown in Figure 6a was typical of eight
metaphases examined in detail and revealed no obvious abnor-
malities. Similarly, there was no evidence of loss of heterozy-
gosity at the p21wAF, pS7K1P2,p53, or pRB-l loci (Fig. 6b) .
However, it was noted that the fastest growing clone HMCT15
did show allelic loss at the INK4 locus (pISINK4B, pI4ARF, and
p 16INK4A),despite possessing a normal unmethy lated p 161NK4A
gene. The improved proliferation rate of HMCT 15 relative (0
the other clones might therefore have been caused by reduced
expression of the p 161NK4Aor pl51NK4Bproteins brought about
by haplo-insufficiency. However, the levels of both pl51NK4B
and p161NK4Ain HMCT15 are similar to early passage HMC
cultures (Fig. 6a). Taken together, the data show that the
HMCTERT clones are genetically stable.
HMC cells expressing telomerase show no
evidence of neoplastic transformation
In contrast to HeLa cells, the HMCTERT clones all failed
to proliferate in 0.2% serum-containing medium (Fig. 7a). They
resembled normal early-passage HMCs and if anything prolif-
erated slightly less than the HMC controls under these condi-
tions. The same clones also failed to proliferate in agar, unlike
HeLa cells (Figs. 7b and 7c). Therefore the HMCTERT clones
have not undergone neoplastic change.
TERT-expressing HMCs can regenerate
striated muscle in vivo
The expression of hTERT has been reported not to interfere
with the differentiation program in HMCs without life span ex-
tension (Seigneurin-Venin et al., 2000a). To test whether our
cultures with extended life span could still differentiate and re-
constitute human striated muscle in vivo, we transplanted them
1480 WOOTTON ET AL.
0 0
o, o,
~ ~ L{)
'<t (V) ..- N (V) '<t ..-
lri co l- I- l- I- l-
N (V) W W W W W
l- I- Z Z Z Z zn::: n::: 0 0 0 0 0 :>w w _j _j _j _j _j ..-a l- I- 0 0 0 0 0 (V) ::.:: I- :j0 0 0 0 0 0 er: LL (1l0 0 I 0 LL~ ~ ~ ~ ~ ~ ~ ~ 0 > (1l LL
I I I I I I I I m (f) I I
r
p16
p21
p15
ERK
b
HMC T2 T3 T4 T15 OOK SCC15 HEK H2O
n primers
unmethylated form
I primers
methylated form
..-.. .. ,.
0 0
o, 11.
~ ~ L{)
'<t (V) ..- N (V) '<t ..-
lri eo l- I- l- I- l-
N (V) W W UJ UJ UJ
l- I- Z Z Z Z zn::: n::: 0 0 0 0 0w w _j _j _j _j _j 0 I- (V)
l- I- 0 0 0 0 0 .<0 ;2 ::i I-U U U 0 0 0 0 0 0 (V)C ..- n::: I~ ~ ~ ~ ~ ~ ~ ~ I- ::::;) WI I I I I I I I I , I Z
c-rnyc
J3-tubulin
FIG. S. The cyclin-dependent kinase inhibitor and c-myc status of the HMCTERT cultures. a: Western blots of p 161NK4A,
P151NK4B,and p21WAFmaintained for up to 70 mean population doublings (MPOs) in culture (30 MPOs beyond the senescence
checkpoint for HMCNeo cultures). The negative control for pl61NK4Awas BICR31, a cell line that is deleted for the INK4A lo-
cus (Munro et al., 1999,2001). The positive control was SV6-IHFK ERK2 was used as a loading control. b: The figure shows
the p161NK4Aproducts obtained using n (unmethylated form) and I (methylated form) sets of primers (Baur et al., 1999). Simi-
lar results were seen with m (unmethylated form) and k (methylated form) sets of primers (data not shown). Line SCC-15 served
as a positive control for methylated pl61NK4Aand cel1line OOK and normal human epidermal keratinocytes (HEK) as controls
for the unmethylated p 161NK4A.c: Western blot of c-myc levels in the HMCTERT cultures that shows no large increase in the c-
myc levels for up to 70 MPOs in culture. The loading control was l3-tubulin.
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FIG.7. Expression of hTERT in human muscle cells (HMC) does not result in neoplastic transformation. a: Proliferation of
HMCTERT clones in low levels of fetal bovine serum is minimal and is less than early passage HMC cells. He La cells were
able to undergo considerable proliferation under the same culture conditions. HeLa cells were used as a positive control line and
normal HMC cells at early passage were used as negative controls. b: The HMCTERT clones fail to proliferate in suspension
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The colonies were counted and photographed after 5 weeks. c: Quantification of the experiment shown in Figure 5b.
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FIG. 8. The HMCTERT clones can reconstitute fully differentiated muscle fibers in vivo. This figure shows the results of ex-
periments in which HMC clones T2 and Tl5 were grafted into the damaged muscle of irradiated RAG-I mice. 8-C: Hematoxylin
and eosin stained muscle grafts and control. a: HMCT2 showing evidence of healthy muscle fibers. b: HMCTI5, as in (a). c: Un-
grafted muscle showing no mature or healthy regenerating muscle fibers. d: Graft of HMCTI, stained with a human specific an-
tispectrin antibody and showing evidence of a submembranous accumulation of the protein. e: Normal human muscle stained
with the same antibody. f: A control graft with no added human muscle cells shows no specific staining. g: Normal mouse mus-
cle showing no specific staining. Scale bar = 50 fLm (a-c) and 25 fLm (d-g). Arrows in (d) indicate human spectrin positive mus-
cle fibres that were considered to have fused (see Table I).
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into RAG-I mice (Watt et al., 1982) in which a localized area
of trauma had been produced. HMCTl5 engrafted more effi-
ciently, in keeping with its high proliferation rate in vitro. Fig-
ure 8 shows the presence of healthy mature muscle fibers in
grafts from both HMCT2 (Fig. 8a) and HMCT15 (Fig. 8b). In
contrast, grafts of late-passage control HMCs and ungrafted
controls (Fig. 8c) show no evidence of regeneration. The hu-
man grafts also stained positively with a human specific spec-
trin antibody confirming their human origin (Fig. 8d), in con-
trast to the nongrafted controls (Fig. 8f) and normal mouse
muscle (Fig. 8g). The submembranous staining pattern in the
HMCTI-engrafted muscle was observed in 28% of the muscle
fibers present in the graft close to the injection site and resem-
bled that of normal human muscle (Fig. 8e). Quantitation of the
number of spectrin positive fibers present in the grafts (Table I)
showed that the number of fused muscle fibers in the tel omer-
ase expressing clone HMCT2 was at least as high as in the early
passage HMC controls (28.4% vs. 24.8%). Thus the HMC
clones that display a considerable extension of proliferative life
span can still undergo fusion and reconstitute mature striated
muscle in vivo, and these observations are consistent with pre-
vious reports that telomerase expression does not disrupt the
differentiation program of HMC cells (Seigneurin- Veninet al.,
2000a,b).
DISCUSSION
There are encouraging signs that gene therapy for DMD and
perhaps other diseases may be possible (Wang et al., 2000a)
but there is also evidence to suggest that muscle gene therapy
in humans may fail, unless the telomeres of the recipient cells
are repaired, to allow sufficient replicative capacity of the ge-
netically corrected cells (Webster and Blau, 1990; Decary et
al., 2000). Therefore, we decided to investigate whether the
replicative life span of human muscle cells could be extended
by the ectopic expression of hTERT, without compromising ge-
nomic stability, analogous to the previous observations made
with human fibroblasts (Bodnar et al., 1998; Vaziri and Benchi-
mol, 1998; Jiang et al., 1999; Morales et al., 1999).
We have shown here that the expression of hTERT can ex-
tend the telomeres of HMCs and extend the proliferative life
span of both mass cultures derived from two different donors
and four of five of the clones tested. Although it is well estab-
lished that telomerase expression itself does not cause genomic
instability (Jiang et al., 1999; Morales et al., 1999) and that it
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protects cells from chromosomal fusions (Mitchell et al., 1999;
Artandi et al., 2000), cells immortalized by telomerase under
certain cu Iture cond itions do show karyotypic changes (Farwell
et al., 2000). Furthermore, all previous successful attempts to
extend the replicative life span of human myoblasts used DNA
tumor viruses and presented no data on the karyology of the
cells (Lochmuller et al., 1999; Seigneurin- Venin et al., 2000b).
Significantly, therefore, we show here that hTERT can extend
the life span of HMCs for up to 40 MPDs, without causing
gross karyotypic alterations. The cells were not transformed and
were still able to reconstitute human striated muscle when
grafted into RAG-l mice, confirming earlier studies, which
showed that the ectopic expression of hTERT does not disrupt
the ability of HMCs to reconstitute normal striated muscle in
vivo (Seigneurin-Venin et al., 2000a,b).
Epithelial cells cannot be fully rejuvenated to early-passage
growth rates with hTERT alone (Kiyono et al., 1998; Dickson
et al., 2000; Ramirez et al., 200 I), and generally, rapid growth
rates in TERT -expressing epithelial cells is accompanied by the
loss of p 161NK4A. Interestingly, the fastest growing clone,
HMCT15, did show loss of heterozygosity (LOH) at the INK4
locus but no reduction in the levels of pl51NK4Bor pl61NK4A,
at least prior to 70 MPDs. Furthermore, HMCTI5 showed a
normal karyotype so the LOH of INK4 was not the result of an
obvious karyotypic change. The levels of CDKI expression did
not correlate with HMCTERT clonal growth rate. Furthermore,
there was no evidence of p16[NK4Amutation, deletion,or methy-
lation in any of the HMC clones studied. The levels of c-myc
protein, which is sometimes upregulated in hTERT-expressing
celis (Wang et al., 2000b), did not correlate with the growth
rate of the HMCTERT cultures and was much lower than the
levels expressed by cancer cell lines. The growth rate of the
TERT-expressing mass HMC cultures and four of the five
clones studied was stable, arguing against secondary events in
the extension of life span in these clones. However, in one of
the clones, HMCTI, unknown secondary events did appear to
contribute to the bypass of senescence, as the clone assumed a
much faster growth rate at later passage.
Our experiments led to the bypass of senescence in HMCs
after the expression of hTERT alone, where previous attempts
did not, despite an increase in the average TRF length
(Seigneurin- Venin et al., 2000a,b). One possible explanation is
that we used DMEM, while other groups have used Ham's FlO,
or derivatives thereof and it has recently been reported that the
choice of culture conditions can influence the impact of telo-
mere-independent senescence mechanisms (Ramirez et al.,
TABLE1. COMPARISONOF THENUMBEROF FUSEDMUSCLECELLS INXENOGRAPTSOF
NORMALHMCs ANDTHETELOMERASE-ExPRESSINGHMC CLONE,HMCT2
Muscle graft
Number of spectrin-
positive fibersltotal
number of fibers
Percentage of spectrin-
positive fibers
Normal cultured human
muscle cells
HMC T2
26/105 24.8
31211099 28.4
HMC, human muscle cells.
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2001). We showed that when our HMC cells were cultured in
Ham's FlO medium rather than DMEM they showed a trun-
cated replicative life span and that two of the telomerase-ex-
pressing HMC clones (HMCT2 and HMCTl5) rapidly under-
went senescence when transferred from DMEM to Ham's FlO
medium. These observations underline the importance of de-
veloping improved culture media for the growth of HMC cells
in the future. There are many differences in the formulations of
Ham's FlO and DMEM, including the inclusion of biotin, thi-
amine, and vitamin Bl2 in the former and a sixfold higher cal-
cium concentration in the latter. Testing the impact of these
variables may aid the quest for improved HMC culture condi-
tions in the future. Another difference between our work and
that of previous investigators is that we removed G418 selec-
tion as soon as the mock-infected cultures had died and it has
been documented that maintaining human keratinocytes under
continuous G418 selection reduces their replicative life span
(Morgan et al., 1987).
The great variability in the proliferation rate of the HMC-
TERT clones that bypassed the senescence checkpoint could
not be completely explained by c-myc, CDKI, or telomerase
levels, or by average TRF length. However, it is possible that
hTERT is able to bypass senescence more efficiently in HMC,
which are at a particular stage of differentiation. With respect
to this, it will be interesting to transduce hTERT into bone mar-
row HMC stem cells (Ferrari et al., 2001).
Our results could have implications for the expansion of
human muscle cell populations in general but in particular as
an aid to the gene therapy of the muscle dystrophies. where
the proliferative capacity of the target HMC is low because
of premature replicative senescence (Webster and Blau, 1990;
Decary et al., 1997). However, it should be stressed that al-
though the culture conditions we have reported here are su-
perior to those used previously, they are still not fully capa-
ble of rejuvenating normal diploid myoblasts and it is possible
that the generation of reactive oxygen species in cell culture
may be responsible for the slow growth rate of most of the
hTERT-expressing myoblast clones (Ramirez et al., 2001).
This problem may eventually be solved by the use of antiox-
idants or culturing cells under low oxygen conditions (Wei et
al., 2001).
A further problem is that although telomerase does not
transform cells (Jiang et al., 1999; Morales et ai., 1999), the
expression of telomerase may facilitate the development of tu-
mors by contributing to the immortalization process (Counter,
1996; Counter et al., 1998) or by other, as yet unidentified,
mechanisms (Gonzalez-Suarez et al., 2001; Stewart et al.,
2002). The transient expression of hTERT using the Cre re-
combinase and hTERT flanked by loxP sites (Wang et al.,
2000b) could be used to extend the length of short telomeres
in myoblasts and thus increase their replicative potential.
These rejuvenated HMCs would then make better targets
for various forms of gene therapy. However, the use of
hTERT in such therapies is dependent on the establishment
of the improved myoblast culture conditions described above
and our data represents an important step toward this objec-
tive.
Our work also opens up the opportunity to obtain long-lived,
genetically stable HMC lines from biopsies of patients with
1485
muscular diseases to serve as valuable human in vitro models
of these diseases.
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